WO2007026185A2 - A pharmaceutical composition containing an extract of a medicinal herb belonging to the order of violales - Google Patents
A pharmaceutical composition containing an extract of a medicinal herb belonging to the order of violales Download PDFInfo
- Publication number
- WO2007026185A2 WO2007026185A2 PCT/HU2006/000071 HU2006000071W WO2007026185A2 WO 2007026185 A2 WO2007026185 A2 WO 2007026185A2 HU 2006000071 W HU2006000071 W HU 2006000071W WO 2007026185 A2 WO2007026185 A2 WO 2007026185A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viola
- violet
- extract
- mitochondrial
- diseases
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 241000219171 Malpighiales Species 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 72
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 35
- 239000007787 solid Substances 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 18
- 108090000790 Enzymes Proteins 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 230000006676 mitochondrial damage Effects 0.000 claims abstract description 14
- 238000005728 strengthening Methods 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 18
- 230000004899 motility Effects 0.000 claims description 15
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 14
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 12
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 208000021642 Muscular disease Diseases 0.000 claims description 7
- 201000009623 Myopathy Diseases 0.000 claims description 7
- 230000017531 blood circulation Effects 0.000 claims description 7
- 230000005989 gallbladder dysfunction Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 3
- 244000172533 Viola sororia Species 0.000 description 88
- 241000405217 Viola <butterfly> Species 0.000 description 78
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 62
- 244000047670 Viola x wittrockiana Species 0.000 description 45
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 39
- 239000013543 active substance Substances 0.000 description 36
- 210000003470 mitochondria Anatomy 0.000 description 34
- 230000006870 function Effects 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 27
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- 239000008103 glucose Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 20
- 241000394559 Viola purpurea Species 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 14
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 14
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 13
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- -1 astringent Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 10
- 241000280995 Viola pallens Species 0.000 description 10
- 230000008437 mitochondrial biogenesis Effects 0.000 description 10
- 210000001187 pylorus Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000394515 Viola macloskeyi Species 0.000 description 9
- 241000394567 Viola pubescens Species 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 208000003770 biliary dyskinesia Diseases 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 244000059558 Viola cucullata Species 0.000 description 8
- 240000009038 Viola odorata Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004898 mitochondrial function Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000005070 sphincter Anatomy 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 7
- 241000294590 Viola chamissoniana Species 0.000 description 7
- 241000394600 Viola vallicola Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000000391 smoking effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 208000009505 Sphincter of Oddi Dysfunction Diseases 0.000 description 6
- 235000013954 Viola cucullata Nutrition 0.000 description 6
- 241000280998 Viola lobata Species 0.000 description 6
- 244000225942 Viola tricolor Species 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003405 ileum Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 206010047139 Vasoconstriction Diseases 0.000 description 5
- 244000154870 Viola adunca Species 0.000 description 5
- 241000394440 Viola arvensis Species 0.000 description 5
- 241000394473 Viola beckwithii Species 0.000 description 5
- 241001583478 Viola biflora Species 0.000 description 5
- 241000313593 Viola canina Species 0.000 description 5
- 241000394523 Viola kauaensis Species 0.000 description 5
- 241001123003 Viola palustris Species 0.000 description 5
- 241000394563 Viola praemorsa Species 0.000 description 5
- 241000394597 Viola umbraticola Species 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 239000006286 aqueous extract Substances 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000011435 rock Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 230000025033 vasoconstriction Effects 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010012666 Diabetic gastropathy Diseases 0.000 description 4
- 208000000289 Esophageal Achalasia Diseases 0.000 description 4
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 description 4
- 206010021518 Impaired gastric emptying Diseases 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 206010030136 Oesophageal achalasia Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 241000220289 Pedunculata Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000005811 Viola adunca Nutrition 0.000 description 4
- 241000280987 Viola lanceolata Species 0.000 description 4
- 235000013487 Viola odorata Nutrition 0.000 description 4
- 241000078745 Viola orientalis Species 0.000 description 4
- 240000007438 Viola pedata Species 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 201000000621 achalasia Diseases 0.000 description 4
- 210000003486 adipose tissue brown Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 208000001130 gallstones Diseases 0.000 description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 4
- 230000007661 gastrointestinal function Effects 0.000 description 4
- 208000001288 gastroparesis Diseases 0.000 description 4
- 230000001969 hypertrophic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 230000010627 oxidative phosphorylation Effects 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 3
- 244000057715 Canadian white violet Species 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 108010058432 Chaperonin 60 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 208000007238 Postcholecystectomy Syndrome Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000059560 Viola canadensis Species 0.000 description 3
- 241000647308 Viola epipsila Species 0.000 description 3
- 241000280991 Viola glabella Species 0.000 description 3
- 241000313598 Viola labradorica Species 0.000 description 3
- 244000304948 Viola papilionacea Species 0.000 description 3
- 235000013488 Viola pedata Nutrition 0.000 description 3
- 241000394606 Viola rotundifolia Species 0.000 description 3
- 241000394605 Viola striata Species 0.000 description 3
- YLRJRFOZRJMCAN-KBPBWVMUSA-O Violanin Natural products O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc3c(-c4cc(O)c(O)c(O)c4)[o+]c4c(c(O[C@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)c3)O2)O[C@H]1C)/C=C/c1ccc(O)cc1 YLRJRFOZRJMCAN-KBPBWVMUSA-O 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 description 3
- 230000003680 myocardial damage Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004514 sphincter of oddi Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000003699 striated muscle Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- DIJCILWNOLHJCG-UHFFFAOYSA-N 7-amino-2',7'-difluoro-3',6'-dihydroxy-6-(methylamino)spiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC(F)=C(O)C=C2OC2=CC(O)=C(F)C=C2C21OC(=O)C1=C(N)C(NC)=CC=C21 DIJCILWNOLHJCG-UHFFFAOYSA-N 0.000 description 2
- SZCBXWMUOPQSOX-UHFFFAOYSA-N 9Z-violaxanthin Natural products O1C(CC(O)CC2(C)C)(C)C12C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 SZCBXWMUOPQSOX-UHFFFAOYSA-N 0.000 description 2
- 102000002281 Adenylate kinase Human genes 0.000 description 2
- 108020000543 Adenylate kinase Proteins 0.000 description 2
- 241001554360 Anchietea Species 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000009193 Caveolin Human genes 0.000 description 2
- 108050000084 Caveolin Proteins 0.000 description 2
- 241000844959 Corynostylis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 241000394591 Hybanthus Species 0.000 description 2
- 241001249552 Hymenanthera Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001126925 Lobata Species 0.000 description 2
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 2
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 244000304944 Missouri violet Species 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241001671251 Rinorea Species 0.000 description 2
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 235000013953 Viola canadensis Nutrition 0.000 description 2
- 241000616640 Viola cornuta Species 0.000 description 2
- 241001047482 Viola hederacea Species 0.000 description 2
- 241001509068 Viola hirta Species 0.000 description 2
- 241001438001 Viola nuttallii Species 0.000 description 2
- 241000487263 Viola palmata Species 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 240000003439 Viola patrinii Species 0.000 description 2
- 241000281003 Viola renifolia Species 0.000 description 2
- 241001584696 Viola riviniana Species 0.000 description 2
- 241001281428 Viola sempervirens Species 0.000 description 2
- 235000012544 Viola sororia Nutrition 0.000 description 2
- 241001253755 Viola walteri Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008436 biogenesis Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229940105847 calamine Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229910052864 hemimorphite Inorganic materials 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- FIAAVMJLAGNUKW-VQVVXJKKSA-N isovitexin 8-C-beta-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O FIAAVMJLAGNUKW-VQVVXJKKSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002840 nitric oxide donor Substances 0.000 description 2
- 230000001129 nonadrenergic effect Effects 0.000 description 2
- 230000002536 noncholinergic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 2
- SZCBXWMUOPQSOX-ACEWEDQGSA-N (1r,3s,6s)-6-[(1e,3e,5e,7e,9z,11e,13e,15e,17e)-18-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-3-ol Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-ACEWEDQGSA-N 0.000 description 1
- DYUUPIKEWLHQGQ-KYHIUUMWSA-N (3S, 5R, 6S, 3'R, 6'R)-5,6-epoxy-5,6-dihydro- beta,epsilon-carotene-3,3'-diol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC3C(=CC(O)CC3(C)C)C DYUUPIKEWLHQGQ-KYHIUUMWSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ODBRNZZJSYPIDI-UHFFFAOYSA-N 3',4',5,7-tetrahydroxy-6-C-glucopyranosylflavone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000169676 Achariaceae Species 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000893024 Ancistrocladaceae Species 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000218999 Begoniaceae Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000934828 Bixaceae Species 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000219172 Caricaceae Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 240000002754 Chenopodium giganteum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- IFYMEZNJCAQUME-APKWKYNESA-N Chrysanthemaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C IFYMEZNJCAQUME-APKWKYNESA-N 0.000 description 1
- 241000984092 Cistaceae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000934836 Cochlospermaceae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108060002063 Cyclotide Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- BJTLSPOVXMBXRZ-UHFFFAOYSA-N DAF-FM dye Chemical compound OC(=O)C1=C(N)C(NC)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BJTLSPOVXMBXRZ-UHFFFAOYSA-N 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 241001117813 Datiscaceae Species 0.000 description 1
- 206010071634 Deficiency of bile secretion Diseases 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 241000125240 Dimorpha Species 0.000 description 1
- PVNVIBOWBAPFOE-UHFFFAOYSA-N Dinoxanthin Natural products CC1(O)CC(OC(=O)C)CC(C)(C)C1=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 PVNVIBOWBAPFOE-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241001106480 Fouquieriaceae Species 0.000 description 1
- 241000893026 Frankeniaceae Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010062693 Gallbladder enlargement Diseases 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710147599 Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 description 1
- 101001036709 Homo sapiens Heat shock protein beta-1 Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000577547 Homo sapiens Nuclear respiratory factor 1 Proteins 0.000 description 1
- 101000605014 Homo sapiens Putative L-type amino acid transporter 1-like protein MLAS Proteins 0.000 description 1
- 241000767665 Hybanthus calycinus Species 0.000 description 1
- 241000394594 Hybanthus concolor Species 0.000 description 1
- 244000057795 Kirks violet Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000169635 Lacistemataceae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001098499 Lanceolata Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- PTNJRKBWIYNFSY-UHFFFAOYSA-N Lirinin-O-methyl-ether Natural products COc1ccc-2c(CC3N(C)CCc4cc(OC)c(OC)c-2c34)c1 PTNJRKBWIYNFSY-UHFFFAOYSA-N 0.000 description 1
- 241001523547 Loasaceae Species 0.000 description 1
- DYUUPIKEWLHQGQ-UWYDEOQVSA-N Lutein 5,6-epoxide Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@]23C(C)(C)C[C@H](O)C[C@@]2(C)O3)\C)/C)\C)/C)C(C)(C)C1 DYUUPIKEWLHQGQ-UWYDEOQVSA-N 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- 241001249546 Malesherbiaceae Species 0.000 description 1
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 235000002255 Missouri violet Nutrition 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GKXJWSZPLIKUPS-IUNAMMOKSA-N N-[(2Z,6Z)-2,6-bis(hydroxyimino)cyclohexylidene]hydroxylamine Chemical compound O\N=C1\CCC\C(=N\O)C1=NO GKXJWSZPLIKUPS-IUNAMMOKSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 102100028744 Nuclear respiratory factor 1 Human genes 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- RBVAFYCFAFADAG-UHFFFAOYSA-N Orientin Natural products OCC1OC(C(O)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4)C(O)C1O RBVAFYCFAFADAG-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000017946 PGC-1 Human genes 0.000 description 1
- 108700038399 PGC-1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000218995 Passifloraceae Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000004262 Pinguicula vulgaris Nutrition 0.000 description 1
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 102100038206 Putative L-type amino acid transporter 1-like protein MLAS Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- YXHFXGHAELQJGK-PGPONNFDSA-N Scoparin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=C([C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C(O)=CC(O)=C3C(=O)C=2)=C1 YXHFXGHAELQJGK-PGPONNFDSA-N 0.000 description 1
- RTRPDMVGOFRVOY-UHFFFAOYSA-N Scoparin Natural products COc1cc(ccc1O)C2=CC(=O)c3c(O)cc(O)c(OC4OC(CO)C(O)C(O)C4O)c3O2 RTRPDMVGOFRVOY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- WJJFWGUVMIUWGG-UHFFFAOYSA-N Stereolensin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O WJJFWGUVMIUWGG-UHFFFAOYSA-N 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000893011 Tamaricaceae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000190080 Turneraceae Species 0.000 description 1
- FIAAVMJLAGNUKW-UHFFFAOYSA-N UNPD109131 Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C(C(O)C(O)C(CO)O2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O FIAAVMJLAGNUKW-UHFFFAOYSA-N 0.000 description 1
- LQSNPVIQIPKOGP-UHFFFAOYSA-N UNPD159785 Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O LQSNPVIQIPKOGP-UHFFFAOYSA-N 0.000 description 1
- 241001314298 Verbascum sinuatum Species 0.000 description 1
- FIAAVMJLAGNUKW-CRLPPWHZSA-N Vicenin 2 Natural products O=C1c2c(O)c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)c(O)c([C@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)c2OC(c2ccc(O)cc2)=C1 FIAAVMJLAGNUKW-CRLPPWHZSA-N 0.000 description 1
- 241000510764 Villosa Species 0.000 description 1
- 241001533304 Viola acuminata Species 0.000 description 1
- 244000303856 Viola adunca var. adunca Species 0.000 description 1
- 241000394450 Viola affinis Species 0.000 description 1
- 240000008240 Viola arcuata Species 0.000 description 1
- 241001281434 Viola bakeri Species 0.000 description 1
- 240000000760 Viola betonicifolia Species 0.000 description 1
- 241001437304 Viola bicolor Species 0.000 description 1
- 241000394475 Viola blanda Species 0.000 description 1
- 241000394471 Viola blanda var. palustriformis Species 0.000 description 1
- 241001302667 Viola brevistipulata Species 0.000 description 1
- 244000029947 Viola canadensis var. canadensis Species 0.000 description 1
- 235000014895 Viola canadensis var. scariosa Nutrition 0.000 description 1
- 235000014891 Viola canadensis var. scopulorum Nutrition 0.000 description 1
- 241000343486 Viola collina Species 0.000 description 1
- 244000107368 Viola confusa Species 0.000 description 1
- 241000394486 Viola cuneata Species 0.000 description 1
- 241000268804 Viola diffusa Species 0.000 description 1
- 241001281436 Viola douglasii Species 0.000 description 1
- 241001302428 Viola grypoceras Species 0.000 description 1
- 241001281435 Viola guadalupensis Species 0.000 description 1
- 241000358049 Viola guestphalica Species 0.000 description 1
- 241000394503 Viola helenae Species 0.000 description 1
- 244000136184 Viola japonica Species 0.000 description 1
- 235000008611 Viola japonica Nutrition 0.000 description 1
- 241001302461 Viola keiskei Species 0.000 description 1
- 241000313596 Viola lactea Species 0.000 description 1
- 241001486609 Viola lanaiensis Species 0.000 description 1
- 241000394527 Viola langsdorffii Species 0.000 description 1
- 240000008203 Viola lutea Species 0.000 description 1
- 244000021370 Viola lutea subsp calaminaria Species 0.000 description 1
- 241000394519 Viola macloskeyi subsp. pallens Species 0.000 description 1
- 241000394507 Viola maviensis Species 0.000 description 1
- 241001509072 Viola mirabilis Species 0.000 description 1
- 241001486607 Viola oahuensis Species 0.000 description 1
- 241000375756 Viola pedatifida Species 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 241000394571 Viola pinnata Species 0.000 description 1
- 241000281006 Viola primulifolia Species 0.000 description 1
- 241000267237 Viola prionantha Species 0.000 description 1
- 241000394555 Viola pubescens var. scabriuscula Species 0.000 description 1
- 241000244254 Viola rostrata Species 0.000 description 1
- 241000313625 Viola rosulata Species 0.000 description 1
- 241000313624 Viola rupestris Species 0.000 description 1
- 241000280947 Viola sagittata Species 0.000 description 1
- 241001302471 Viola selkirkii Species 0.000 description 1
- 241000394602 Viola sheltonii Species 0.000 description 1
- 235000002251 Viola sororia var novae angliae Nutrition 0.000 description 1
- 244000304961 Viola sororia var. novae angliae Species 0.000 description 1
- 241000527948 Viola tokubuchiana Species 0.000 description 1
- 241001281430 Viola tomentosa Species 0.000 description 1
- 241000280943 Viola vaginata Species 0.000 description 1
- 241000078743 Viola variegata Species 0.000 description 1
- 241001302465 Viola violacea Species 0.000 description 1
- 241000294625 Viola wailenalenae Species 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- PGYAYSRVSAJXTE-CLONMANBSA-N all-trans-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-CLONMANBSA-N 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 244000057731 hookedspur violet Species 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ODBRNZZJSYPIDI-VJXVFPJBSA-N isoorientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-VJXVFPJBSA-N 0.000 description 1
- UYJGIAWJIRZBNU-UHFFFAOYSA-N isoorientin Natural products OCC1OC(C(O)C(O)C1O)c2cc(O)c(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4 UYJGIAWJIRZBNU-UHFFFAOYSA-N 0.000 description 1
- MYXNWGACZJSMBT-VJXVFPJBSA-N isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MYXNWGACZJSMBT-VJXVFPJBSA-N 0.000 description 1
- OYJCWTROZCNWAA-UHFFFAOYSA-N isovitexin Natural products OCC1OC(C(O)C(O)C1O)c2c(O)cc3CC(=CC(=O)c3c2O)c4ccc(O)cc4 OYJCWTROZCNWAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- DYUUPIKEWLHQGQ-FJOIUHRLSA-N lutein 5,6-epoxide Chemical compound C(/[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C DYUUPIKEWLHQGQ-FJOIUHRLSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000005165 macula densa Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000014978 mitochondrial calcium ion transport Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- OWAAYLVMANNJOG-OAKWGMHJSA-N neoxanthin Natural products CC(=C/C=C(C)/C=C/C=C(C)/C=C=C1C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OWAAYLVMANNJOG-OAKWGMHJSA-N 0.000 description 1
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 235000014887 northern bog violet Nutrition 0.000 description 1
- 244000241526 northern woodland violet Species 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- PLAPMLGJVGLZOV-VPRICQMDSA-N orientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-VPRICQMDSA-N 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- PUIBPGHAXSCVRF-QHFGJBOXSA-N prostaglandin C1 Chemical compound CCCCC[C@H](O)\C=C\C1=CCC(=O)[C@@H]1CCCCCCC(O)=O PUIBPGHAXSCVRF-QHFGJBOXSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 244000030924 tall white violet Species 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- CSNXTSWTBUEIJB-UHFFFAOYSA-N vicenin-II Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C(OC2C(C(O)C(O)C(CO)O2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O CSNXTSWTBUEIJB-UHFFFAOYSA-N 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- YULKMYVXBQKDFK-PWPBMSJASA-N vitri a Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(N1)=O)CSSC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC=1C4=CC=CC=C4NC=1)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)CN)CSSC3)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(NCC(=O)N2)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 YULKMYVXBQKDFK-PWPBMSJASA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention refers to a pharmaceutical composition containing an extract of a medicinal herb belonging to the order of Violales or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient.
- the composition is useful for increasing the mitochondrial genesis as well as for the prevention and/or treatment of diseases due to damages of the mitochondrion or a reduced function of the enzyme constitutive nitric oxide synthase. Background of the invention
- Damages of the mitochondrion plays an important role in the formation of several diseases, while other diseases are developped owing to disturbances in the constitutive nitric oxide synthase system.
- the mitochondrion is an essential organelle of the cell which occurs in varying number in the cytoplasm of every cell. That is the site of the cell's energy production. 98 % of the oxygen used by the human organism is applied by the mitochondria for energy production. Oxidative phosphorylation taking place in the mitochondrion produces a considerable amount of ATP (adenosine triphosphate) that stores the energy needed by the cell. Thus, the number and state of mitochondria is determinative from the point of view of life. In function of physical requirement, the oxidative capacity of the striated muscle is able to change by an order of magnitude. The myofibrillar protein type of the muscle is changed and the mitochondrion content of the muscle is increased during accomodation to the load.
- the transcription factor PGC-1 ⁇ of the coactivator PPAR ⁇ has key role.
- Mitochondrial biogenesis is also influenced by the calcium/calmoduline dependant kinase IV (CaMKIV), calcineurine, AMP-kinase [Zong H et al.: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation, Proc. Natl. Acad. Sci., 99, 15983 (2002)], MEF2 (myocyte enhancer factor 2), p38 MAPK as well as CREB, however, their effect is produced mainly through PGC-1 ⁇ [Nisoli E.
- CAMKIV and calcineurin have an indirect influence on the activity of the promoter of PGC-1 ⁇ , while p38 MAPK exerts its effect through the phosphorylation of PGC-1 ⁇ and delaying the effect of the endogenic inhibiting domain [Fan M. et al., Genes & Development, 18 ⁇ .278 (2004)].
- the nitric oxide produced by the endothelial nitric oxide synthase enzyme - through the increase of the activity of the guanilate cyclase enzyme and the cGMP level - plays a fundamental part in inducing the expression of PGC-1 ⁇ and, thus, in the regulation of mitochondrial genesis [Nisoli, E.: Mitochondrial biogenesis in mammals. The role of endogenous nitric oxide. Science, 299, 896 (2003)].
- the mitochondrion takes part also in the regulation of other physiological processes, for example, it plays a role in the regulation of the insulin secretion of ⁇ -cells, in the oxygen perception of the pulmonary vessels as well as the sinus caroticus.
- the mitochondrion contains the key enzymes that define the rate of steroid biosynthesis and the carbonic acid anhydrase enzyme that is essential for the secretion of gastric acid.
- the mitochondrion has a great part in the regulation of calcium signalization through the uptake of cytosolic calcium [Gunter T. E. et al.: Mitochondrial calcium transport: mechanism and functions, Cell Calcium, 28 ⁇ 285 (2000)].
- the heat generation ability of the brown adipose tissue is based on the detachment of oxidative phosphorylation, however, this process is only of secondary importance in man.
- the mitochondrion is of key importance in the regulation of the programmed cell death (apoptosis) [Martinou J. C, Green D. R.: Breaking the mitochondrial barrier, Nat Rev. MoI. Cell. Biol., 2 ⁇ 63 (2001)].
- the damage of mitochondrion is the cause of several diseases.
- a specific mutation of mitochondrial DNA results in the development of type I or insulin-dependent diabetes mellitus [Maassen J. A. et al.: Mitochondrial diabetes: molecular mechanisms and clinical presentation, Diabetes, 53 Suppl 1, 103 (2004)].
- the basic disorder that starts the patomechanism consists in a reduced sensitivity of the tissues against insulin i.e. insulin resistance.
- a reduced oxidative phosphorylation capacity of the mitochondria can be in the background of insulin resistance [Petersen K. F.
- PGC-1 ⁇ reduced levels were detected in patients suffering from type Il diabetes mellitus [Patti, M. et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , PNAS, 100, 8466 (2003)].
- the mitochondrial dysfunction has a causal role in inducing the change of protein conformation, partly, the damaged mitochondrion itself becomes a target of the metabolic cascade induced by the change of protein conformation, thus, contributing to the progression of the disease.
- the mitochondrial dysfunction results in the desctruction of nerve cells primarily through enhanced free radical formation, reduced energy generation, disorder of calcium homeostasis and endoplasmatic reticulum.
- Nitric oxide is a ubiquitous signal transducer molecule having very significant regulatory roles. Nitric oxide has an important role in the vasodilation through the relaxation of the smooth musculation of vessels. The aggregation and activation of blood platelets as well as the proliferation of the smooth muscle cells of vessel are inhibited by nitric oxide that plays a role also in the regulation of heart muscle contraction and relaxation. Nitric oxide is essential in the regulation of the motility of the gastrointestinal tract, primarily through inhibiting the contraction of the sphincters e.g. pylorus (or pyloric sphincter) [Huang P. L., Am. J. Cardiol., 82, 57S (1998); Takahashi T., J. Gastroenterol., 38, 421 (2003)].
- sphincters e.g. pylorus (or pyloric sphincter)
- Nitric oxide is produced from L-arginine by at least three different enzymes [neuronal nitric oxide synthase (nNOS, NOS1), inducible nitric oxide synthase (iNOS, NOS2) and endothelial nitric oxide synthase (eNOS, NOS3)].
- nNOS neuronitric oxide synthase
- iNOS inducible nitric oxide synthase
- eNOS endothelial nitric oxide synthase
- Neuronal type nitric oxide synthase is predominantly expressed in specific neurons of the brain, in non-adrenergic, non-cholinergic autonomic nerve cells, in muscles and in the macula densa region of the renal tubules, however, it is present at lower level in many other tissues as well.
- nNOS enzyme elevation of intracellular Ca ++ concentration and protein phosphorylation plays an immediate role.
- recent observations have revealed that the alteration of the expression level of the enzyme has a significant effect on the regulation of the activity thereof, too [Sasaki, M. et al., Proc. Natl. Acad. Sci. USA, 97, 8617 (2000)].
- nNOS knockout animals revealed a series of disease conditions where impaired nNOS enzyme function had significant role in the pathogenesis [Mashimo, H., Am. J. Physiol., 277, 745 (1999)].
- the proper motility of the whole gastrointestonal tract, especially the relaxation of sphincters, depends on the activation of nNOS in non- adrenergic, non-cholinergic neurons [Takahashi, T., J. Gastroenterol., 38, 421 (2003)].
- Nitric oxide produced by the nNOS enzyme regulates the muscle tone of the sphincter in the lower esophagus, pylorus, anus and the sphincter of Oddi through the inhibition of contraction.
- nNOS knockout mice gastric dilatation and stasis develop due to the long evacuation of the stomach.
- the level and function of nNOS expression is severely damaged in both type I and type Il diabetes with the consequence that a dysfunction of the gastrointestinal system occurs in about 75 % of the patients.
- Diabetic gastropathy syndrome is characterized by prolonged gastric emptying, flatulence, nausea, vomiting, abdominal pain that deteriorate life quality [Koch K. L., Dig. Dis. Sci., 44, 1061 (1999)].
- gastrointestinal motility and function disturbances in the pathomechanism of which the reduced nNOS function may have significant role include achalasia, hypertrophic pylorus stenosis, Hirschprung's disease, functional digestion disorders, ileus and colitis. Significant therapeutical effect can be expected in these diseases by restoring the nNOS function. Also in simple hypermotility disorders, favourable effects can be awaited through the enhancement of the nNOS function and the restoration of the local neuronal reflexes.
- Nitric oxide formation mediated by the nNOS enzyme has an essential role also in the regulation of the urinary bladder.
- the unsufficient expression and activity of the enzyme may be a cause of urinary retention.
- the enzyme plays a fundemental role in the erection of penis [Cuevas A.J. et al, Biochem. Biophys. Res. Commun., 312, 1202], therefore, the unsufficient activity of nNOS enzyme, mainly as a consequence of diabetes, is a frequent cause of erectile disfunctions.
- nNOS enzyme activity has an essential role in normal muscle function primarily by attenuating vasoconstriction, thus, allowing adequate blood supply.
- Recent data indicate that in certain muscle degenerations, for example in Duchene muscular distrophy, also the function of nNOS enzyme is damaged [S. Froehner, Trends in Molecular Medicine, 8, 51 (2002)]. Restoration of the inadequate nNOS function improved the symptoms of the disease in animals.
- nNOS enzyme can be responsible also for diseases related to aggressive behaviour since animal studies indicate that diminished expression and function of the enzyme result in serotonin dysfunction (descreased serotonin turnover, deficient serotonin receptor function) leading to aggressive behaviour [Chiavegatto, S. et al., Proc. Natl. Acad. Sci. USA, 98, 1277 (2001)]. It is believed that deficient nNOS function has a role in disease patterns related to aggressive behaviour and certain disturbances of sexual attitude.
- Nitric oxide may have both pro- and anti-apoptic effect. Based on experimental observations, the suitable activity of the enzyme is essential in different nerve regeneration processes e.g. for recovery in traumatic peripheral nerve lesion [Keilhoff, G. Et al., Cell. MoI. Biol., 49, 885 (2003)]. Nitric oxide donors can be useful in the inhibition or treatment of arteriosclerosis [Herman, A.G. es Moncada, S.: Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis, Eur. Heart J., 2005 May 25].
- the inactive eNOS enzyme is attached to the caveolin in the membrane. During activation, eNOS separates from the caveolin and form complexes with other proteins. To achieve perfect activation, phosphorylation by Akt kinase and PKC-A kinase is needed [Nedvetsky et al., PNAS, 99, 16510 (2002)].
- Nitric oxide produced by endothelial nitric oxide synthase plays a role in the regulation of blood pressure [Huang et al.: Hypertension in mice lacking the gene for endothelial nitric oxide synthase, Nature, 377, 239 (1995)], and the reduced enzyme function contributes to the development of hypertension [Forte et al.: Basal nitric oxide synthesis in essential hypertension, Lancet, 349, 837 (1997)].
- eNOS stimulated by insulin is deficient resulting in a reduced glucose uptake of the muscles [Steinberg et al.: Obesity/insulin resistance is associated with endothelial dysfunction, J. Clin. Invest., 97, 2601 (1996)].
- a reduced eNOS function or applicability was shown which contributed to the progression of the disease.
- nNOS and eNOS are jointly called as constitutive nitric oxide synthase (eNOS) enzyme.
- Smoking results in a disorder of the system that produces constitutive nitric oxide partly due to the direct inactivation of neuronal and endothelial nitric oxide synthase enzymes [Lowe, E. R. et al.: Time-dependent inactivation and tetrahydro- biopterin depletion of endothelial nitric oxide synthase caused by cigarettes, Drug Metab. Dispos., 33, 131 (2005)].
- mitochondrial damage as well as the reduced function of constitutive nitric oxide synthase enzyme may develop various diseases. Although some of the diseases can be treated with available synthetic drugs, however a drawback of synthetic drugs resides in the side-effects, often highly disagreeable unwanted effects thereof. In addition, there is no drug presently available that could restore the activity of the nNOS enzyme in different tissues or could achieve mitochondrial genesis.
- the aim of the invention is the prevention or treatment of diseases related with mitochondrial damage and/or a reduced function of cNOS enzyme by a pharmaceutical composition based on a medicinal herb extract.
- Viola odorata are used, in general, for the treatment of chronic bronchitis, pertussis and asthma bronchiale due to the expectorant and antitussive properties of the plant, however, the relieving action of Viola odorata in case of migraine is also known.
- the leaves of Viola odorata are considered to be effective in case of hoarseness, sore throat, impairments of sleep and neurosis.
- the active agents of Viola tricolor include the following ones: flavonoids such as rutin, quercetin, luteolin, luteolin-7-glycoside, scoparin, saponarin, saponaretin, violantin, orientin and isoorientin, vicenin-2 and vitexin [Hansel R. et al.: publication cited above].
- Violarvensin is a flavone di- C-glycoside isolated from the related genus field pansy (Viola arvensis) [Camat, A. P., Camat, A., Fraisse, D., Lamaison J.
- carotenoids that can be isolated from the plant include violaxanthin and derivatives thereof [Hansmann, P., Kleinig, H.: Violaxanthin esters from Viola tricolor flowers, Phytochemistry, 21, 238-239 (1982); Molnar, P., Szabolcs, J.: Occurence of 15-cis-violaxanthin in Viola tricolor, Phytochemistry, 19, 623-627 (1980); Molnar, P., Szabolcs, J., Radios, L.: Naturally occuring di-cis-violaxanthins from Viola tricolor: Isolation and identification by 1 H NMR spectroscopy of four di-cis-isomers, Phytochemistry, 25, 195-199 (1986); Radios, L., Molnar, P., Szabolcs, J.: 13 C NMR evidence for the central mono-cis- stereochemistry of naturally occuring
- Phenolcarboxylic acids and the derivatives thereof trans- and cis-coumaric acid, gentisic acid, p-hydroxy-benzoic acid, 4-hydroxyphenylacetic acid, trans-caffeic acid, protocatechuic acid, vanillic acid, salicylic acid and derivatives thereof are important components [Hansel R. et al.: publication cited above].
- polysaccharides based on glucose, galactose, arabinose, ramnose, xylose and uronic acid, furthermore vitamines E and C, triacylglycerol as well as fatlike substances are to be mentioned [Hansel R. et al.: publication cited above].
- Cyclic peptides such as vitri A, vary A and E isolated from the species Viola tricolor were found to be cytotoxic on certain human tumor cell lines [Svangard, E., Goransson, U., Hocaoglu, Z., Gullbo, J., Larsson, R., Claeson, P., Bohlin, L.: Cytotoxic Cyclotides from Viola tricolor, J: Nat. Prod., 67, 144- 147 (2004)].
- Data referring to the antioxidant properties of the species Viola tricolor were published by Mantle et al. [Mantle, D., Eddeb, F., Pickering A. T.: Comparison of relative antioxidant activities of British medicinal plant species in vitro, J.
- composition or pharmaceutical composition containing an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient optionally in addition to one or more conventional pharmaceutical carrier(s).
- the composition or pharmaceutical composition of the invention is suitable for the enhancement of mitochondrial genesis as well as for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme. The most important diseases of these type have been discussed above. Description of preferred embodiments
- Hybanthus concolor (T.F. Forst) Spreng Hybanthus linearifolius (Vahl) Urban Rinorea genus ⁇ Rinorea moagalensis Anchietea genus ⁇ Anchietea salutans Corynostylis genus -> Corynostylis hybnanthus
- Viola glabella pioneer violet stream violet
- Viola grypoceras Viola grypoceras
- Viola odorata sweet violet ; garden violet; etc.
- Viola orientalis Viola orientalis
- Viola pedata birdfoot violet Viola pedata birdfoot violet; bird's foot violet; etc.
- Viola prionantha Viola prionantha
- Viola violacea Viola violacea
- Viola x bernardii Bernard's violet Viola x bissellii Bissell's violet
- Viola x cooperrider Viola x cooperrider
- Viola yedoensis Viola yedoensis
- Viola tricolor Viola arvensis
- Viola odorata Viola tricolor
- the extract is prepared in a manner known perse.
- the part of the herb that has grown above the earth is extracted.
- the extraction is carried out with water or an organic solvent such as an alcohol e.g. ethanol, or an aqueous solution of an organic solvent e.g. aqueous ethanol generally at 0-100 0 C, preferably at 20-100 0 C.
- an organic solvent such as an alcohol e.g. ethanol, or an aqueous solution of an organic solvent e.g. aqueous ethanol generally at 0-100 0 C, preferably at 20-100 0 C.
- mixing is applied, however, ultrasonication can be used, too.
- the extract is separated from the parts of the plant by known methods using e.g. sedimentation, pressing of the parts of the plant, filtration, centrifugation or the combination of the procedures listed.
- the extract obtained can be used as it is or it can be converted to a liquid composition or pharmaceutical composition such as an aqueous solution or syrup. However, it is preferred to remove the solvent content of the extract for example by evaporation, spray drying or freeze drying, and the solid residue is used as an active agent for the preparation of a composition or a pharmaceutical composition.
- the expression ,,active agent is used in this sense and it refers to the solid residue that is dissolved in the extract and can be obtained from the extract of the medicinal herb.
- Both the extract and the solid residue obtained from the extract can be characterized by the determination of the flavonoid and polyphenol contents. For example, the flavonoid content of the solid residue amounts to 2.8-3.4 g/100 g, and the total polyphenol content is 9.7-11.0 g/100 g.
- a known formulation or dosage form which is conventionally used for the prevention or treatment of diseases and which is suitable for peroral, parenteral, rectal or transdermal administration or for local treatment.
- the pharmaceutical composition of the invention is solid or liquid and contains, in addition to the active substance obtained from the medicinal herb by extraction, one or more pharmaceutical carrier(s).
- the pharmaceutical composition of the invention contains, in general, 0.1-100 % by mass, preferably 1-50 % by mass, suitably 5-30 % by mass of the active ingredient. It is to be noted that a 100 % content of active ingredient is possible only in certain cases e.g. in capsules where dilution is not absolutely necessary. In most dosage forms, diluents and/or other auxiliary agents are needed for the preparation of the pharmaceutical composition.
- the solid pharmaceutical compositions suitable for peroral administration may be powders, capsules, tablets, film-coated tablets, microcapsules etc., and can comprise binding agents such as gelatine, sorbitol, poly(vinylpyrrolidone) etc.; filling agents such as lactose, glucose, starch, calcium phosphate etc.; auxiliary substances for tabletting such as magnesium stearate, talc, poly(ethylene glycol), silica etc.; wetting agents such as sodium laurylsulfate etc. as the carrier.
- binding agents such as gelatine, sorbitol, poly(vinylpyrrolidone) etc.
- filling agents such as lactose, glucose, starch, calcium phosphate etc.
- auxiliary substances for tabletting such as magnesium stearate, talc, poly(ethylene glycol), silica etc.
- wetting agents such as sodium laurylsulfate etc. as the carrier.
- the liquid pharmaceutical compositions suitable for peroral administration may be solutions, suspensions or emulsions and can comprise e.g. suspending agents such as gelatine, carboxymethylcellulose etc.; emulsifiers such as sorbitane monooleate etc.; solvents such as water, oils, glycerol, propylene glycol, ethanol etc.; preservatives such as methyl or propyl p-hydroxybenzoate etc. as the carrier.
- suspending agents such as gelatine, carboxymethylcellulose etc.
- emulsifiers such as sorbitane monooleate etc.
- solvents such as water, oils, glycerol, propylene glycol, ethanol etc.
- preservatives such as methyl or propyl p-hydroxybenzoate etc. as the carrier.
- compositions suitable for parenteral application contain, in general, a sterile solution of the active agent.
- compositions suitable for local treatment include solutions, creams, liniments etc.
- the pharmaceutical composition contains dosage unit, in general.
- the daily dose can be administered in one or more portions.
- the actual dosage depends on many factors and is determined by the doctor.
- a typical dose for adult patients of 70 kg body weight amounts to 0.1 to 10 g, preferably 1 to 5 g of active agent, daily.
- the pharmaceutical composition is prepared by admixing the active ingredient to one or more carrier(s) and transforming the mixture obtained into a pharmaceutical composition in a manner known perse.
- the methods that can be used are known from the literature e.g. the manual Remington's Pharmaceutical Sciences cited above.
- the solid residue obtained from the extract can be directly filled into capsules or the extract itself can be converted to a liquid pharmaceutical composition by the addition of further carriers, if needed.
- the composition administered is not necessarily a pharmaceutical composition, however, the contents and preparation thereof corresponds to those of the pharmaceutical compositions described herein. Consequently, the expression ..composition” used in the description and claims without the marking ..pharmaceutical” refers to a dosage form that is applied to induce favourable biological effects related to mitochondrial genesis, however, such treatment is not definitely medication.
- the thoracic aorta of a pig was excised, aseptically, and placed into a PBS solution containing 50 ⁇ g/ml of streptomycin for transport (PBS is a physiological saline that contains phosphate buffer).
- PBS is a physiological saline that contains phosphate buffer.
- the connective tissue was removed from the aorta which latter was cut to pieces of several cm length, and the rings obtained were opened.
- a sterile, close-meshed plastic net impregnated with trypsin (0.25 % of trypsin in PBS) was placed onto the surface covered by endothelium and the tissues were kept at 37 0 C for 1 or 2 minute(s).
- the endothelium layer loosened under the action of trypsin was removed by washing, the cells were collected by centrifugation, then removed to culturing dishes coated with collagen and grown in a 1 :1 mixture of DMEM (Dulbecco's modified Eagle's medium) culture medium (GibcoBRL, Eggenstein, Germany) supplemented with 10 % of FCS (fetal calf serum) and F-12.
- DMEM Dulbecco's modified Eagle's medium
- FCS fetal calf serum
- F-12 fetal calf serum
- the cortex of an 8 day's old Wistar rat was removed aseptically, cut into pieces, and the cells were set free by diggestion with trypsin (0.08 % of trypsin in PBS).
- the larger pieces of tissue were removed, the fraction containing individual cells and lumps consisting of some cells was washed twice with RPMI (Roswell Park Memorial Institute) culture medium containing 10 % of FCS.
- RPMI Roswell Park Memorial Institute
- the cells suspended in RPMI culture medium containing 10 % of FCS were placed into grow dishes (Greiner) without special surface treatment and grown at 37 0 C under an atmosphere containing 5 % of carbon dioxide.
- a mixed cell culture was obtained containing mainly glia (astrocyte, oligodendrocyte and microglia) cells. Cells obtained in the first passage were used in the tests.
- Human immortalized HaCaT skin cells were grown in a DMEM culture medium containing 10 % of FCS in dishes (Greiner) without special surface treatment at 37 0 C under an atmosphere containing 5 % of carbon dioxide.
- the culture medium was supplemented with 25 mM or 50 mM of D-glucose and the cells were grown for at least 1 week in this culture medium.
- the cells were incubated with 100 nM of the fluorescent stain MitoTracker at 37 0 C for 30 minutes.
- the stain cumulating in the active mitochondria exhibits a fluorescent emission at 516 nm following an excitation at 490 nm.
- the fluorescence of the mitochondria was determined partly in a microscope, partly using a FACS (fluorescence activated cell sorter) apparatus.
- FACS fluorescence activated cell sorter
- a fluorescence microscope Zeiss-Axioskop was employed. Exposures were prepared with a Nicon Coolpix 995 digital camera using identical exposure time, diaphragm aperture and digital picture size. The exposures were evaluated by densitometry.
- the intensity of the cell fluorescence is proportional to the amount of mitochondria.
- the observation under a microscope allows the study of the morphology of the mitochondrial network.
- EDTA ethylenediaminetetraacetic acid
- the insoluble cell debris was removed by centrifugation (13000 g, 12 minutes, +4 0 C). The clear supernatant was admixed to VT. volume of 2x Laemmli gel loading buffer, the samples were boiled for 3 minutes, then maintained at -20 0 C before use. The protein concentration was determined by means of Bio-Rad D 0 Protein Assay reagent (Bio-Rad Laboratories, Hercules, California, USA).
- the fluorescence of DAF-FM (excitation peak at 490 nm, emission peak at 515 nm) becomes 160-times higher, therefore it is suitable for the measurement of the amount of intracellular NO.
- the DAF specific fluorescence of the cells in the lymphocyte cell fraction was determined by means of a Becton Dickinson FACS Calibur apparatus.
- NMRI mice having a body mass of 23-25 g were treated, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 for 4 days.
- the animals were anaesthetized by an injection of pentobarbital [5-ethyl-5-(1-methylbutyl)-2,4,6- (1 H,3H,5H)-pyrimidintrione], and samples were taken from the brown adipose tissue of the animals. Then, the level of proteins in the tissue was determined.
- mice having a body mass of 25 g were treated, once daily, with a dose of 30 or 100 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 for 5 days, wherein each group consisted of 5 mice.
- the animals were anaesthetized by an injection of pentobarbital, blood was drawn from the corner of the eye and the glucose level was determined from the blood using an AccuCheck glucose meter. Then, 2 g of glucose/kg body weight were administered, intraperitoneally, and blood glucose levels were determined in the animals 30, 60 and 90 minutes after the glucose administration.
- the mice of the control group were treated with an identical amount of the carrier (i.e. distilled water).
- diabetes was induced by the intravenous administration of 60 mg/kg of streptozocin.
- the blood sugar level of the animals was determined from the fourth week following the induction of diabetes, weekly, and the animals having stable high blood sugar level (>20 mM/litre) were drawn into the test after the tenth week.
- the 7 animals of the test group were treated orally, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 in aqueous solution for 5 days, while the 7 animals of the control group were treated with an identical volume of physiological saline.
- the 7 animals of the test group were treated orally, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 in aqueous solution for 5 days, while the 7 animals of the control group were treated with an identical volume of physiological saline.
- the thoracic aorta was removed and placed into ice cold Krebs' solution containing 118,0 mM of sodium chloride, 4,7 mM of potassium chloride, 2,52 mM of calcium chloride, 1 ,64 mM of magnesium sulfate, 24,88 mM of sodium hydrogen carbonate, 1 ,18 mM of potassium dihydrogen phosphate and 11 ,0 mM of D-glucose.
- a gas mixture consisting of 95 % of oxygen and 5 % of carbon dioxide was led through the solution, constantly.
- the descending aorta was cut to obtain rings of 5 mm width, the rings were suspended in a Krebs' solution at 37 0 C using 2 g of initial load under constant introduction of the oxygen gas, contracted with phenylephrine [(R)-3-hydroxy- ⁇ -[(methylamino)methyl]- benzenemethanol], then the relaxation ability of the rings was determined based on the relaxation response to increasing doses of acetylcholin. The measurements were carried out in an lsosys System apparatus (Experimetria, Budapest, Hungary).
- the treatment carried out with a dose of 16 ug/ml of the active substance prepared from Viola tricolor in aqueous solution for 4 days resulted in a 20 % increase of the fluorescence characterizing the amount of mitochondria compared with the control.
- the strengthening of the mitochondrial network could be observed after the treatment in this case, too.
- COX-IV protein In addition to the direct determination of the mitochondrial number, an increase of the level of COX-IV protein could be also noticed on Western blot. It is to be noted that the COX-IV protein is specific of mitochondrion and plays a key role in oxidative phosphorylation, thus, the increase of the level thereof indicates the increase of the amount of mitochondria. It was found that the COX-IV protein level increased by 60 % compared with the control in the primary pig endothelial cell culture owing to the treatment for 4 days with a dose of 8 ⁇ g/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution.
- the COX-IV protein level increased by 430 % compared with the control due to the treatment for 4 days with a dose of 16 ⁇ g/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution.
- Increase of the expression of cNOS and HSP Nitric oxide synthetized especially by the endothelial nitric oxide synthase (eNOS) enzyme is rather important in the regulation of mitochondrial function and biogenesis.
- Nitric oxide enhances the expression of the transcription factor PGC- 1 ⁇ , the main regulator of mitochondrial biogenesis.
- the amount of cytosolic eNOS was higher by about 60 % in pig endothelial cells due to the treatment for 4 days with a dose of 8 ⁇ g/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution. Cytosolic eNOS is considered to be active.
- the heat shock proteins (chaperons) HSP72 and HSP90 are extremely important in the formation and stabilization of the functionally active eNOS complex.
- the amount of HSP90 ⁇ increased by 10 %, while the level of HSP72 increased by 130 % compared with the untreated control due to the treatment of the invention.
- the HSP72 has a key role also in the import of mitochondrial proteins. This coordinated import of protein is essential for the normal mitochondrial function and biogenesis.
- a culture medium having a higher glucose content (25 mM) than the normal blood sugar level is used for growing human immortalized HaCaT keratinocyte cells.
- the cells adapted themseves to the high glucose concentration. Therefore, in order to simulate the hyperglycaemic environment, the concentration of glucose was raised by further 25 mM and the cells were grown in this culture medium. Based on staining with MitoTracker, the mitochondrion content of the cells grown in the culture medium containing 25 mM of glucose was higher by 30 % than that of the cells grown under hyperglycaemic circumstances in a culture medium containing 50 mM of glucose. This observation corresponds to the known fact that a hyperglycaemic environment deteriorates mitochondria.
- the cell culture pretreated with 50 mM of glucose was treated for 4 days with a dose of 4 ⁇ g/ml of the active substance prepared from the medicinal herb Viola tricolor.
- the treatment raised the amount of mitochondria by 20 % i.e. the treatment could partly combat the hyperglycaemic effect.
- the proteins examined by us and having a key role in the mitochondrial genesis were expressed only in the smallest amount.
- the amount of PGC-1 ⁇ increased by a factor of 8
- that of HSP90 ⁇ and HSP72 increased by a factor of 6
- that of HSP60 increased by a factor of 3
- that of COX-IV protein increased by a factor of 3.
- the brown adipose tissue of NMRI mice treated for 4 days with a dose of 30 mg/kg of the active substance prepared from the medicinal herb Viola tricolor contained the heat shock protein HSP90 ⁇ in a higher amount by 120 % and the heat shock proteins HSP72 and HSP60 in a higher amount by 60 % compared with the control group without treatment. Due to the treatment, the level of heat shock protein HSP25 having an important role in the regulation of the redox processes of cells was also higher by 60 %. This in vivo test result indicates that the active substance extracted from the medicinal herb Viola tricolor is absorbed and exerts its effect also in vivo.
- the treatment of the invention improved also the glucose tolerance in mouse.
- the blood sugar levels expressed in nM and determined before the i.p. administration of 2 g/kg of D- glucose (0 minute), then after 30, 60 and 90 minutes following the administration are given in Table I for the control group and the test groups treated with an i.p. dose of 30 or 100 mg/kg of the active substance extracted from the medicinal herb Viola tricolor.
- mice having a body mass of 23-25 g were treated, once, with a dose of 200 mg/kg of the active substance, intraperitoneally.
- the behaviour of the animals was evaluated for a week, neither any change of behaviour, nor weight loss was experienced.
- an i.p. dose of 200 mg/kg of the active substance extracted from the medicinal herb Viola tricolor does not result in an acute toxic effect in mice.
- the chaperons (HSP70, HSP90, HSP60, HSP27) partly contribute to the formation and stabilization of the functionally active cNOS complex, partly have an important role in the transport of mitochondrial proteins as well as in the compensation of any oxidative load (e.g. hyperglycaemia).
- an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient provides for a curing effect in case of disorders owing to a damage of the mitochondrion or a reduced function of the cNOS enzyme; advantages can be awaited in states or diseases when an increase of mitochondrial genesis is useful; furthermore, diseases connected with a damage of the mitochondrion or the reduced function of the cNOS enyzme can be prevented by applying said extract or active ingredient.
- An extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient can be effective especially in the following states: I. Through exerting an influence on the mitochondrial function and promoting the mitochondrial biogenesis a) States and diseases requiring fast mitochondrial regeneration:
- Gall bladder dysfunctions e.g. pyloric sphincter, sphincters of the anus.
- vasoconstriction Damages caused by smoking especially vasoconstriction, thrombosis, arteriosclerosis, chronic bronchitis, pulmonary emphysema.
- composition or pharmaceutical composition of the invention containing an extract of a part of a medicinal herb belonging to the order of Violates, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is suitable for:
- a preferred embodiment of the invention refers to the use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a composition suitable for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal.
- composition of the invention containing the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, as the active ingredient and one or more carrier(s) is suitable for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal.
- a preferred composition of the invention is a roborant composition that improves the physical condition of the body after illness or anorexia or in case of muscle development trainings.
- a preferred embodiment of the invention refers to the use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a pharmaceutical composition suitable for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases comprising ALS, Parkinson's disease, Alzheimer's disease and Atkinson's disease, and/or myopathies comprising cardiomyopathy, and/or metabolic diseases comprising diabetes, insulin resistance, metabolic syndrome and obesity, and/or motility disorders of the gastrointestinal system comprising achalasia, infantile hypertrophic pylorus stenosis, Hirschprung's disease, diabetic gastropathy, reflux oesophagitis, gastrointestinal function disorder in case of diabetes, gastroparesis, functional dyspepsia, intestinal pseudoobstruction, colitis, common motility disorders of the gastrointestinal system and dysfunction of sphincters, and/or gall bladder
- a preferred embodiment of the pharmaceutical composition of the invention containing the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, as the active ingredient and one or more pharmaceutical carrier(s) is suitable for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases comprising ALS, Parkinson's disease, Alzheimer's disease and Atkinson's disease, and/or myopathies comprising cardiomyopathy, and/or metabolic diseases comprising diabetes, insulin resistance, metabolic syndrome and obesity, and/or motility disorders of the gastrointestinal system comprising achalasia, infantile hypertrophic pylorus stenosis, Hirschprung's disease, diabetic gastropathy, reflux oesophagitis, gastrointestinal function disorder in case of diabetes, gastroparesis, functional dyspepsia, intestinal pseudoobstruction, colitis, common motility disorders of the
- a preferred pharmaceutical composition of the invention is suitable for the prevention or treatment of the motility disorders of the gastrointestinal system, thus, a preferred pharmaceutical composition of the invention is a prokinetic agent that induces movement in the gastrointestinal system.
- An especially preferred pharmaceutical composition of the invention is suitable for the prevention or treatment of reflux oesophagitis.
- the invention includes a method for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme, especially neurodegenerative diseases, myopathies, metabolic diseases, motility disorders of the gastrointestinal system, gall bladder dysfunctions, disorders of the blood circulation or damage of the skin surface owing to ultraviolet light in which the patient being in need thereof is treated with a therapeutically effective amount of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient.
- the aqueous extract obtained is worked up as described under process A.
- the aqueous extract has a dry matter content of 5.7-6.2 mg/ml.
- the lyophilized product (i.e. active substance) prepared as given under process A has a flavonoid content of 2.8-3.1 g/100 g, total polyphenol content of 10.1-11.0 g/100 g , and total content of polyphenol in the skin powder of 1.9-2.2 g/100 g.
- 0.5 g portions of the lyophilized active substance prepared according to Example 1 , process B are filled into hard gelatin capsules, the capsules are closed, placed into a glass container that is sealed airtightly..
- process A dry matter content: 5.8 mg/ml
- 20 ml of glycerol 100 ml of 70 % aqueous sorbitol solution, 0.1 g of aroma substance and 1 g of methyl paraben are added, the mixture is homogenized and filled into bottles of 50 ml.
Abstract
An extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme.
Description
A pharmaceutical composition containing an extract of a medicinal herb belonging to the order of Violales
Field of the invention
The invention refers to a pharmaceutical composition containing an extract of a medicinal herb belonging to the order of Violales or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient. The composition is useful for increasing the mitochondrial genesis as well as for the prevention and/or treatment of diseases due to damages of the mitochondrion or a reduced function of the enzyme constitutive nitric oxide synthase. Background of the invention
Damages of the mitochondrion plays an important role in the formation of several diseases, while other diseases are developped owing to disturbances in the constitutive nitric oxide synthase system.
The mitochondrion is an essential organelle of the cell which occurs in varying number in the cytoplasm of every cell. That is the site of the cell's energy production. 98 % of the oxygen used by the human organism is applied by the mitochondria for energy production. Oxidative phosphorylation taking place in the mitochondrion produces a considerable amount of ATP (adenosine triphosphate) that stores the energy needed by the cell. Thus, the number and state of mitochondria is determinative from the point of view of life.
In function of physical requirement, the oxidative capacity of the striated muscle is able to change by an order of magnitude. The myofibrillar protein type of the muscle is changed and the mitochondrion content of the muscle is increased during accomodation to the load. In the regulation of mitochondrial function and formation, the transcription factor PGC-1α of the coactivator PPARγ (peroxisome proliferator-activated receptor γ) has key role. Mitochondrial biogenesis is also influenced by the calcium/calmoduline dependant kinase IV (CaMKIV), calcineurine, AMP-kinase [Zong H et al.: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation, Proc. Natl. Acad. Sci., 99, 15983 (2002)], MEF2 (myocyte enhancer factor 2), p38 MAPK as well as CREB, however, their effect is produced mainly through PGC-1α [Nisoli E. et al.: Mitochondrial biogenesis as a cellular signaling framework, Biochemical Pharmacology 67, 1 (2004.)]. CAMKIV and calcineurin have an indirect influence on the activity of the promoter of PGC-1α, while p38 MAPK exerts its effect through the phosphorylation of PGC-1 α and delaying the effect of the endogenic inhibiting domain [Fan M. et al., Genes & Development, 18^.278 (2004)]. According to recent observations, the nitric oxide produced by the endothelial nitric oxide synthase enzyme - through the increase of the activity of the guanilate cyclase enzyme and the cGMP level - plays a fundamental part in inducing the expression of PGC-1α and, thus, in the regulation of mitochondrial genesis [Nisoli, E.: Mitochondrial biogenesis in
mammals. The role of endogenous nitric oxide. Science, 299, 896 (2003)].
In addition to the energy production, the mitochondrion takes part also in the regulation of other physiological processes, for example, it plays a role in the regulation of the insulin secretion of β-cells, in the oxygen perception of the pulmonary vessels as well as the sinus caroticus. The mitochondrion contains the key enzymes that define the rate of steroid biosynthesis and the carbonic acid anhydrase enzyme that is essential for the secretion of gastric acid. The mitochondrion has a great part in the regulation of calcium signalization through the uptake of cytosolic calcium [Gunter T. E. et al.: Mitochondrial calcium transport: mechanism and functions, Cell Calcium, 28^285 (2000)]. The heat generation ability of the brown adipose tissue is based on the detachment of oxidative phosphorylation, however, this process is only of secondary importance in man. The mitochondrion is of key importance in the regulation of the programmed cell death (apoptosis) [Martinou J. C, Green D. R.: Breaking the mitochondrial barrier, Nat Rev. MoI. Cell. Biol., 2^63 (2001)].
The damage of mitochondrion is the cause of several diseases. A specific mutation of mitochondrial DNA results in the development of type I or insulin-dependent diabetes mellitus [Maassen J. A. et al.: Mitochondrial diabetes: molecular mechanisms and clinical presentation, Diabetes, 53 Suppl 1, 103 (2004)]. In the type Il or noninsulin-dependent diabetes mellitus, the basic disorder that starts the
patomechanism consists in a reduced sensitivity of the tissues against insulin i.e. insulin resistance. According to recent examinations, a reduced oxidative phosphorylation capacity of the mitochondria can be in the background of insulin resistance [Petersen K. F. et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance, Science 300, 1140; Petersen K. F. et al.: Impaired mitochondrial activity in the insulin resistant offspring of patients with type Il diabetes, N. Engl J. Med., 350, 665 (2004)]. A genetic relation between the PGC-1α gene playing a key role in the regulation of mitochondrion function and mitochondrion biogenesis on the one hand, and obesity and diabetes on the other hand was shown in Danish and Japanese population [Ek, J. et al., Diabetologia, 44, 2220 (2001); Hara et al., Diabetologia, 45, 740 (2002)]. Furthermore, reduced levels of PGC-1α were detected in patients suffering from type Il diabetes mellitus [Patti, M. et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , PNAS, 100, 8466 (2003)].
Several chronic neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease and ALS (amyotrophic lateral sclerosis) are accompanied by damaged mitochondrial function. It is deemed that the damage of mitochondria contributes to the progression of the disease [Scon E. A., Manfredi G., J. Clin. Invest., 111 , 303 (2003)]. In these chronic neurodegenerative diseases, a change of conformation of certain neuronal proteins can be
shown, wherein said change is accompanied by the function alteration and aggregation of the proteins. Partly, through the enhanced formation of free radicals, the mitochondrial dysfunction has a causal role in inducing the change of protein conformation, partly, the damaged mitochondrion itself becomes a target of the metabolic cascade induced by the change of protein conformation, thus, contributing to the progression of the disease. The mitochondrial dysfunction results in the desctruction of nerve cells primarily through enhanced free radical formation, reduced energy generation, disorder of calcium homeostasis and endoplasmatic reticulum.
The study of the lifetime of animals revealed that a long lifetime is coupled with a low level of reactive oxygen species (ROS) [Perez-Campo R. et al.: The rate of free radical production as a determinant of the rate of aging: evidence from the comparative approach, J. Comp. Physiol., 168, 149 (1998)]. According to the mostly accepted aging theories, the process of aging is related to the oxidative damage [Hekimi S., Guarente L.: Genetics and specificity of aging process, Science, 299, 1351 (2003)]. The cumulation of mitochondrial defects and the enhanced formation of free radicals are considered as a cause in the development of diseases related to aging [Fridovich, I.: Mitochondria: are they the seat of senescence? Aging Cell, 3, 13 (2004)]. The role of mitochondrion in the aging process is supported by the fact that the point of attack of the genes that enhance lifetime is either the mitochondrion itself or the antioxidant mechanisms
closely connected with the mitochondrion.
The functioning of the constitutive nitric oxide synthase system and its role in the patomechanism of diseases is outlined as follows.
Nitric oxide (NO) is a ubiquitous signal transducer molecule having very significant regulatory roles. Nitric oxide has an important role in the vasodilation through the relaxation of the smooth musculation of vessels. The aggregation and activation of blood platelets as well as the proliferation of the smooth muscle cells of vessel are inhibited by nitric oxide that plays a role also in the regulation of heart muscle contraction and relaxation. Nitric oxide is essential in the regulation of the motility of the gastrointestinal tract, primarily through inhibiting the contraction of the sphincters e.g. pylorus (or pyloric sphincter) [Huang P. L., Am. J. Cardiol., 82, 57S (1998); Takahashi T., J. Gastroenterol., 38, 421 (2003)].
Nitric oxide is produced from L-arginine by at least three different enzymes [neuronal nitric oxide synthase (nNOS, NOS1), inducible nitric oxide synthase (iNOS, NOS2) and endothelial nitric oxide synthase (eNOS, NOS3)].
Neuronal type nitric oxide synthase is predominantly expressed in specific neurons of the brain, in non-adrenergic, non-cholinergic autonomic nerve cells, in muscles and in the macula densa region of the renal tubules, however, it is present at lower level in many other tissues as well. In the activation of nNOS enzyme, elevation of intracellular Ca++ concentration and protein phosphorylation plays an immediate
role. Furthermore, recent observations have revealed that the alteration of the expression level of the enzyme has a significant effect on the regulation of the activity thereof, too [Sasaki, M. et al., Proc. Natl. Acad. Sci. USA, 97, 8617 (2000)].
The examination of nNOS knockout animals revealed a series of disease conditions where impaired nNOS enzyme function had significant role in the pathogenesis [Mashimo, H., Am. J. Physiol., 277, 745 (1999)]. The proper motility of the whole gastrointestonal tract, especially the relaxation of sphincters, depends on the activation of nNOS in non- adrenergic, non-cholinergic neurons [Takahashi, T., J. Gastroenterol., 38, 421 (2003)]. Nitric oxide produced by the nNOS enzyme regulates the muscle tone of the sphincter in the lower esophagus, pylorus, anus and the sphincter of Oddi through the inhibition of contraction. The diminished relaxation of sphincters disturbs the function, in this way e.g. the insufficient relaxation of pylorus (or pyloric sphincter) disturbs the coordinated mechanism of gastric emptying. For example, in nNOS knockout mice, gastric dilatation and stasis develop due to the long evacuation of the stomach. The level and function of nNOS expression is severely damaged in both type I and type Il diabetes with the consequence that a dysfunction of the gastrointestinal system occurs in about 75 % of the patients. Diabetic gastropathy syndrome is characterized by prolonged gastric emptying, flatulence, nausea, vomiting, abdominal pain that deteriorate life quality [Koch K. L., Dig. Dis. Sci., 44, 1061 (1999)]. Insulin treatment that restores
nNOS expression and NO level [Watkins C, J. Clin. Invest., 106, 373 (2000)] or supplementing NO through NO donors eliminates the diabetic gastrointestinal motility disturbance, thus, supporting the pathological role of NO in the disease.
A consequence of insufficient nNOS enzyme activity in the sphincter of Oddi is the syndrome of ,,lazy gall bladder". Owing to the lack of nitric oxide due to nNOS, the relaxation of the sphincter of Oddi is not sufficient resulting in an inhibited flow of bile from the gall bladder which leads to digestive troubles due to acholia as well as to cholecystectasia and cholestasis. The consequence of the latter symptoms is an enhanced risk of inflammatory diseases and formation of gallstones. Since bile plays an essential role in the lipid metabolism, the reduced bile secretion results in higher cholesterol level in the blood which can contribute to the development of metabolic syndrome [JAMA, 285, 2486 (2001 )].
Other gastrointestinal motility and function disturbances in the pathomechanism of which the reduced nNOS function may have significant role include achalasia, hypertrophic pylorus stenosis, Hirschprung's disease, functional digestion disorders, ileus and colitis. Significant therapeutical effect can be expected in these diseases by restoring the nNOS function. Also in simple hypermotility disorders, favourable effects can be awaited through the enhancement of the nNOS function and the restoration of the local neuronal reflexes.
Nitric oxide formation mediated by the nNOS enzyme has an essential role also in the regulation of the urinary
bladder. The unsufficient expression and activity of the enzyme may be a cause of urinary retention.
In a similar way, the enzyme plays a fundemental role in the erection of penis [Cuevas A.J. et al, Biochem. Biophys. Res. Commun., 312, 1202], therefore, the unsufficient activity of nNOS enzyme, mainly as a consequence of diabetes, is a frequent cause of erectile disfunctions.
The nNOS enzyme activity has an essential role in normal muscle function primarily by attenuating vasoconstriction, thus, allowing adequate blood supply. Recent data indicate that in certain muscle degenerations, for example in Duchene muscular distrophy, also the function of nNOS enzyme is damaged [S. Froehner, Trends in Molecular Medicine, 8, 51 (2002)]. Restoration of the inadequate nNOS function improved the symptoms of the disease in animals.
The unsufficient function of nNOS enzyme can be responsible also for diseases related to aggressive behaviour since animal studies indicate that diminished expression and function of the enzyme result in serotonin dysfunction (descreased serotonin turnover, deficient serotonin receptor function) leading to aggressive behaviour [Chiavegatto, S. et al., Proc. Natl. Acad. Sci. USA, 98, 1277 (2001)]. It is believed that deficient nNOS function has a role in disease patterns related to aggressive behaviour and certain disturbances of sexual attitude.
Nitric oxide may have both pro- and anti-apoptic effect. Based on experimental observations, the suitable activity of the
enzyme is essential in different nerve regeneration processes e.g. for recovery in traumatic peripheral nerve lesion [Keilhoff, G. Et al., Cell. MoI. Biol., 49, 885 (2003)]. Nitric oxide donors can be useful in the inhibition or treatment of arteriosclerosis [Herman, A.G. es Moncada, S.: Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis, Eur. Heart J., 2005 May 25].
Recent observations in animals indicate that the reduction of nNOS expression and function significantly contributes to the progression of certain renal diseases (nephrosis, renal damage) [Ni, Z. and Vaziri, N., Biochim. Biophys. Acta, 1638, 129 (2003)].
The inactive eNOS enzyme is attached to the caveolin in the membrane. During activation, eNOS separates from the caveolin and form complexes with other proteins. To achieve perfect activation, phosphorylation by Akt kinase and PKC-A kinase is needed [Nedvetsky et al., PNAS, 99, 16510 (2002)]. Nitric oxide produced by endothelial nitric oxide synthase plays a role in the regulation of blood pressure [Huang et al.: Hypertension in mice lacking the gene for endothelial nitric oxide synthase, Nature, 377, 239 (1995)], and the reduced enzyme function contributes to the development of hypertension [Forte et al.: Basal nitric oxide synthesis in essential hypertension, Lancet, 349, 837 (1997)]. In insulin resistant individuals, activation of eNOS stimulated by insulin is deficient resulting in a reduced glucose uptake of the muscles [Steinberg et al.: Obesity/insulin resistance is associated with endothelial
dysfunction, J. Clin. Invest., 97, 2601 (1996)]. In several cardiovascular diseases, a reduced eNOS function or applicability was shown which contributed to the progression of the disease.
The enzymes nNOS and eNOS are jointly called as constitutive nitric oxide synthase (eNOS) enzyme.
Smoking results in a disorder of the system that produces constitutive nitric oxide partly due to the direct inactivation of neuronal and endothelial nitric oxide synthase enzymes [Lowe, E. R. et al.: Time-dependent inactivation and tetrahydro- biopterin depletion of endothelial nitric oxide synthase caused by cigarettes, Drug Metab. Dispos., 33, 131 (2005)]. Stimulation of the activity of eNOS enzyme moderates the damage caused by smoking [Raveendran et al.: Endogenous nitric oxide activation protects against cigarette smoking induced apoptosis in endothelial cells, FEBS Lett., 579, 733 (2005)]. As it is known, smoking causes damages, primarily, in the vascular system, accelerates the plaque formation on the vessel wall and enhances the risk of blood clot formation [Lakier, J. B.: Smoking and cardiovascular disease, Am. J. Med., 93(1A), 8S-12S (1992); Price, J. F. et al.: Relationship between smoking and cardio-vascular risk factors in the development of peripheral arterial disease and coronary artery disease, Edinburgh Artery Study, Eur. Heart J., 20(5), 344-353 (1999)].
As a summary, it can be stated that mitochondrial damage as well as the reduced function of constitutive nitric oxide
synthase enzyme may develop various diseases. Although some of the diseases can be treated with available synthetic drugs, however a drawback of synthetic drugs resides in the side-effects, often highly disagreeable unwanted effects thereof. In addition, there is no drug presently available that could restore the activity of the nNOS enzyme in different tissues or could achieve mitochondrial genesis.
The aim of the invention is the prevention or treatment of diseases related with mitochondrial damage and/or a reduced function of cNOS enzyme by a pharmaceutical composition based on a medicinal herb extract.
Some of the medicinal herbs belonging to the order of Violales have been widely used in popular medicine. It is known, for example, that the leaf and root of the species Viola odorata have mucolytic, sweltering, blood-cleansing effect, and the flower therof has mucolytic, depressant and blood pressure lowering effect. Based on the expectorant, diuretic, astringent, antiphlogistic and blood-cleansing effect of the species Viola tricolor [Keville K., The Illustrated Encyclopedia of Herbs, Chancellor Press, 302. (1992); Hansel, R., Keller, K., Rimpler H., Schneider, G. 0: Hager's Handbuch der Pharmazeutischen Praxis, Springer verlag, 6. Band, 1141-1153], teas or extracts prepared from the parts of the plant growing above the earth are often used in case of cold as well as inflammatory, skin and arthritic diseases [Leporatti, M. L., Ivancheva, S.: Preliminary comparative analysis of medicinal plants used in the traditional medicine of Bulgaria and Italy, J. Ethnopharm.,
87, 123-142 (2003)]. Certain parts of the species Viola odorata are used, in general, for the treatment of chronic bronchitis, pertussis and asthma bronchiale due to the expectorant and antitussive properties of the plant, however, the relieving action of Viola odorata in case of migraine is also known. The leaves of Viola odorata are considered to be effective in case of hoarseness, sore throat, impairments of sleep and neurosis.
In spite of the fact that the above-mentioned species of Viola are considered as important medicinal herb, the phytochemical analysis thereof is by far not complete.
Based on scientific proofs, the active agents of Viola tricolor include the following ones: flavonoids such as rutin, quercetin, luteolin, luteolin-7-glycoside, scoparin, saponarin, saponaretin, violantin, orientin and isoorientin, vicenin-2 and vitexin [Hansel R. et al.: publication cited above]. Violarvensin is a flavone di- C-glycoside isolated from the related genus field pansy (Viola arvensis) [Camat, A. P., Camat, A., Fraisse, D., Lamaison J. L.: Violarvensin, a New Flavone Di-C-glycoside from Viola arvensis, J. Nat. Prod., 61, 272-274 (1998)]. The presence of triterpene saponins based on uriolic acid and containing galactose and galacturonic acid as the sugar component were confirmed by some authors (Hansel R. et al.), while other authors considered that a protein designed as violapeptide I was responsible for the haemolytic property [Schopke, Th., Hasan Agha, M. I., Kraft, R., Otto, A., Hitler, K.: Haemolytisch aktive Komponenten aus Viola tricolor L. und viola arvensis Murray, Sci. Pharm., 61, 145-153 (1993)]. According to
literature data, carotenoids that can be isolated from the plant include violaxanthin and derivatives thereof [Hansmann, P., Kleinig, H.: Violaxanthin esters from Viola tricolor flowers, Phytochemistry, 21, 238-239 (1982); Molnar, P., Szabolcs, J.: Occurence of 15-cis-violaxanthin in Viola tricolor, Phytochemistry, 19, 623-627 (1980); Molnar, P., Szabolcs, J., Radios, L.: Naturally occuring di-cis-violaxanthins from Viola tricolor: Isolation and identification by 1H NMR spectroscopy of four di-cis-isomers, Phytochemistry, 25, 195-199 (1986); Radios, L., Molnar, P., Szabolcs, J.: 13C NMR evidence for the central mono-cis- stereochemistry of naturally occuring violaxanthin isomers, Phytochemistry, 22, 306 (1983)], violeo- xanthin, lutein, luteinepoxide and neoxanthin [Hansel et al.: publication cited above]. Out of the anthocyans, the presence of delphinidine agliconu violanin, platyconin and violanin chloride is characteristic [Saito, N., Timberlake, C. F., Tucknott, O. G., Lewis, I. A. S.: Fast atom bombardment mass spectrometry of the antho-cyanins violanin and platyconin, Phytochemistry, 22, 1007-1009 (1983)]. Phenolcarboxylic acids and the derivatives thereof: trans- and cis-coumaric acid, gentisic acid, p-hydroxy-benzoic acid, 4-hydroxyphenylacetic acid, trans-caffeic acid, protocatechuic acid, vanillic acid, salicylic acid and derivatives thereof are important components [Hansel R. et al.: publication cited above]. As further components, polysaccharides based on glucose, galactose, arabinose, ramnose, xylose and uronic acid, furthermore vitamines E and C, triacylglycerol as well as fatlike substances are to be
mentioned [Hansel R. et al.: publication cited above].
Cyclic peptides such as vitri A, vary A and E isolated from the species Viola tricolor were found to be cytotoxic on certain human tumor cell lines [Svangard, E., Goransson, U., Hocaoglu, Z., Gullbo, J., Larsson, R., Claeson, P., Bohlin, L.: Cytotoxic Cyclotides from Viola tricolor, J: Nat. Prod., 67, 144- 147 (2004)]. Data referring to the antioxidant properties of the species Viola tricolor were published by Mantle et al. [Mantle, D., Eddeb, F., Pickering A. T.: Comparison of relative antioxidant activities of British medicinal plant species in vitro, J. Ethnopharm., 72, 47-51 (2000)]. Goun et al. described considerable antithrombin activity of Viola tricolor [Goun, E. A., Petrichenko, V. M., Solodnikov, S. U., Suhinina, T. V., Kline, M. A., Cunningham, G., Nguyen, C, Miles, H.: Anticancer and antithrombin activity of Russian plants, J. Ethnopharm., 81, 337-342 (2002)]. The antimalarial property of the species Viola surinamensis were described by Lopes et al. [Lopes, N. P., Kato, M. J., de A. Andrade, E. H., Maia, J. G. S., Yosida, M., Planchart, A. R., Katzin, A. M.: Antimalarial use of volatile oil from leaves of Viola surinamensis (RoI.) Warb. by Waiipi Amazon Indians, J. Ethnopharm., 67, 313-319 (1999)]. The antipyretic effect of the species Viola odorata was published by Khattak et al. [Khattak, S. G., Naeemuddin, G., Ikram, M.: Antipyretic studies on some indigenous Pakistani medicinal plants, J. Ethnopharm., 14, 24-51 (1985)]. This effect can be related to the salicylic acid content of the plant.
Thus, although some of the medicinal herbs belonging to
the order of Violales have been used in the form of a herb tea or extract for the treatment of certain diseases, no pharmaceutical composition has been prepared from these medicinal herbs. Summary of the invention
It has been found that the above aim can be achieved by a composition or pharmaceutical composition containing an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient optionally in addition to one or more conventional pharmaceutical carrier(s). The composition or pharmaceutical composition of the invention is suitable for the enhancement of mitochondrial genesis as well as for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme. The most important diseases of these type have been discussed above. Description of preferred embodiments
Under the expression ,,a medicinal herb belonging to the order of Violales" the following medicinal plants are meant in terms of the taxonomical description: Order: Violales Families: - Vϊolaceae
Viola genus
Hybanthus genus → H.calycinus
Hybanthus concolor (T.F. Forst) Spreng Hybanthus linearifolius (Vahl) Urban
Rinorea genus → Rinorea moagalensis Anchietea genus → Anchietea salutans Corynostylis genus -> Corynostylis hybnanthus
Hymenanthera genus -> Hymenanthera obovata
- Flacourtiaceae
- Lacistemataceae
- Passifloraceae
- Turneraceae
- Malesherbiaceae
- Fouquieriaceae
- Caricaceae
- Bixaceae
- Cochlospermaceae
- Cistaceae
- Tamaricaceae
- Ancistrocladaceae
- Frankeniaceae
- Achariaceae
- Begoniaceae (according to other sources: Salicales)
- Loasaceae
- Datiscaceae
- Samydaceae
- Gucurbitaceae
As for families, there are significant alterations in literature data, therefore, the following species are also considered to belong to the order of Violales:
Viola acuminata acuminate violet
Viola adunca hookedspur violet; western dog violet
Viola adunca var. adunca hookedspur violet
Viola adunca var. kirkii Kirk's violet
Viola adunca var. oxyceras hookedspur violet; sharptail violet
Viola affinis sand violet
Viola appalachiensis Appalachian violet
Viola arvensis field pansy
Viola bakeri Baker's violet
Viola beckwithii Beckwith's violet; Great Basin violet
Viola beckwithii ssp. beckwithii Beckwith's violet
Viola beckwithii ssp. glabrata western pansy
Viola bicolor field pansy
Viola biflora
Viola biflora ssp. biflora twoflower violet
Viola biflora ssp. carlottae Carlott's violet
Viola blanda sweet white violet; willdenow violet; etc.
Viola blanda var. blanda sweet white violet
Viola blanda var. palustriformis sweet white violet; marsh violet
Viola brevistipulata short stipule violet
Viola brittoniana northern coastal violet; coast violet
Viola brittoniana var. brittoniana northern coastal violet
Viola brittoniana var. pectinata combed northern coastal violet
Viola calaminaria Yellow calamine violet
Viola californica California violet
Viola canadensis Canadian white violet; Canada violet; etc.
Viola canadensis var. canadensis Canadian white violet
Viola canadensis var. corymbosa Canadian white violet
Viola canadensis var. rugulosa creepingroot violet
Viola canadensis var. scariosa shriveled Canadian white violet
Viola canadensis var. scopulorum Canadian rock white violet
Viola canina heath violet; dog violet
Viola canina ssp. canina heath dog violet
Viola canina ssp. montana heath dog violet
Viola chamissoniana olopu
Viola chamissoniana ssp. chamissoniana olopu
Viola chamissoniana ssp. robusta large olopu
Viola chamissoniana ssp. tracheliifolia olopu
Viola charlestonensis Charleston Mountain violet
Viola chinensis China violet
Viola collina hillside violet
Viola conspersa American dog violet
Viola cornuta horned violet; bedding pansy
Viola cucullata marsh blue violet
Viola cuneata wedgeleaf violet
Viola diffusa spreading violet
Viola douglasii Douglas' golden violet
Viola egglestonii glade violet
Viola epipsila dwarf marsh violet; large marsh violet
Viola epipsila ssp. repens dwarf marsh violet; creeping marsh violet
Viola flettii Olympic violet; rock violet
Viola frank-smithii Frank-Smith's violet
Viola glabella pioneer violet; stream violet
Viola grypoceras Viola grypoceras
Viola guadalupensis Guadalupe violet
Viola guestphalica Violet calamine violet
Viola hallii Oregon violet
Viola hastata halberd leaf yellow violet
Viola hederacea Australian violet, trailing violet
Viola helenae Wahiawa stream violet
Viola hirsutula southern woodland violet
Viola hirsuta Hairy violet
Viola hispida Rouen pansy
Viola howellu Howell's violet
Viola incognita large leaved white violet
Viola japonica Japanese violet
Viola kauaensis pohe hiwa
Viola kauaensis var kauaensis pohe hiwa
Viola kauaensis var wahiawaensis pohe hiwa
Viola keiskei Viola keiskei
Viola labradorica alpine violet, Labrador violet
Viola lactea pale dog violet
Viola lanaiensis Hawaii violet
Viola lanceolata bog white violet
Viola lanceolata ssp lanceolata lanceleaf bog white violet
Viola lanceolata ssp occidentalis eastern bog white violet
Viola lanceolata ssp vittata bog white violet
Viola langsdorfii Aleutian violet, Alaska violet
Viola lithion rock violet
Viola lobata moosehorn violet, yellow wood violet
Viola lobata ssp integrifolia moosehorn violet
Viola lobata ssp lobata moosehorn violet
Viola lobata var lobata moosehorn violet
Viola lovelhana Lovell's violet
Viola lutea mountain pansy
Viola macloskeyi small white violet, western sweet white violet
Viola macloskeyi ssp macloskeyi Macloskey's violet, western sweet white violet
Viola macloskeyi ssp pallens smooth white violet
Viola mandschurica Manchuπan violet
Viola maviensis Hawaii bog violet
Viola mirabilis wonder violet
Viola missouriensis Missouri violet, banded violet
Viola nephrophylla var nephrophylla northern bog violet
Viola novae-anghae New England blue violet
Viola nuttallii Nuttall's violet; yellow prairie violet
Viola oahuensis Oahu violet
Viola obliqua marsh blue violet
Viola obtusa blunt violet
Viola ocellata pinto violet; two eyed violet
Viola odorata sweet violet; garden violet; etc.
Viola orbioulata darkwoods violet; western round leaved violet
Viola orientalis Viola orientalis
Viola palmata early blue violet; palmate violet; wild okra
Viola palmata var. palmata early blue violet
Viola palustris marsh violet; alpine marsh violet
Viola palustris var. brevipes marsh violet
Viola palustris var. palustris marsh violet
Viola patrinii stemless violet
Viola pedata birdfoot violet; bird's foot violet; etc.
Viola pedatifida prairie violet; prairie birdfoot violet; etc.
Viola pedunculata California golden violet; grass pansy; yellow pansy
Viola pedunculata ssp. pedunculata California golden violet
Viola pedunculata ssp. tenuifolia threadleaf California golden violet
Viola pinetorum goosefoot yellow violet
Viola pinetorum ssp. grisea goosefoot violet
Viola pinetorum ssp. pinetorum goosefoot violet
Viola pinnata pinnate violet
Viola praemorsa canary violet
Viola praemorsa ssp. flavovirens upland yellow violet
Viola praemorsa ssp. linguifolia upland yellow violet
Viola praemorsa ssp. praemorsa canary violet
Viola primulifolia primrose leaved violet
Viola prionantha Viola prionantha
Viola psychodes butterfly violet
Viola pubescens downy yellow violet
Viola pubescens var. peckii Peck's downy yellow violet
Viola pubescens var. pubescens smooth yellow violet
Viola pubescens var. scabriuscula rough yellow violet
Viola purpurea goosefoot violet
Viola purpurea ssp. aurea goosefoot yellow violet
Viola purpurea ssp. dimorpha two formed goosefoot violet
Viola purpurea ssp. geophyta rock goosefoot violet
Viola purpurea ssp. integrifolia entire leaved goosefoot violet
Viola purpurea ssp. nπesophyta goosefoot violet
Viola purpurea ssp. mohavensis Mojave yellow violet
Viola purpurea ssp. purpurea purple goosefoot violet; pine violet
Viola purpurea ssp. quercetorum goosefoot yellow violet
Viola purpurea ssp. venosa goosefoot yellow violet
Viola rafiπesquii field pansy
Viola reichanbachiana slender wood violet
Viola renifolia northern white violet; kidney leaved white violet
Viola renifolia var. renifolia kidneyleaf white violet
Viola rivianawood violet; dog violet
Viola rostrata longspur violet
Viola rotundifolia eastern roundleaf yellow violet; early yellow violet
Viola rupestris Teesdale violet; rock violet
Viola sagittata arrowleaf violet
Viola selkirkii Selkirk's violet
Viola sempervirens evergreen violet; redwood violet
Viola septemloba southern coastal violet
Viola septentrionalis var. septentrionalis northern woodland violet; northern blue violet
Viola sheltonii Shelton's violet
Viola sororaria woolly blue violet
Viola striata striped cream violet; pale violet; striped violet
Viola subsinuata wavy leaf violet
Viola tokubuchiana Viola tokubuchiana
Viola tomentosa feltleaf violet
Viola tricolorJohnnyjump up; heart's-ease; etc.
Viola trinervata Rainier violet; sagebrush violet
Viola tripartita threepart violet
Viola umbraticola Ponderosa violet
Viola umbraticola var. glaberrima Ponderosa violet
Viola umbraticola var. umbraticola Ponderosa violet
Viola utahensis Utah violet
Viola vaginata sheathed violet
Viola vallicola valley violet
Viola vallicola var. major large valley violet
Viola vallicola var. vallicola sagebrush violet
Viola variegata Viola variegata
Viola verecunda hidden violet
Viola viarum twoflower violet; plains violet; wayside violet
Viola villosa Carolina violet; hairy violet; wrinkled violet
Viola violacea Viola violacea
Viola wailenalenae Alakai Swamp violet
Viola walteri prostrate blue violet; prostrate southern violet
Viola x bernardii Bernard's violet
Viola x bissellii Bissell's violet
Viola x brauniae Braun's violet
Viola x conjugens violet
Viola x consobrina violet
Viola x consocia violet
Viola x cooperrider Viola x cooperrider
Viola x cordifolia violet
Viola x davisu Davis' violet
Viola x eamesii Eames' violet
Viola x eclipes violet
Viola x filicetorum violet
Viola x hollickii Hollick's violet
Viola x insolita violet
Viola x luciae Lucy's violet
Viola x malteana violet
Viola x mistura violet
Viola x modesta violet
Viola x mollicula Viola x molilalia
Viola x mulfordiae Mulford's violet
Viola x notabihs violet
Viola x peckiana Peck's violet
Viola x porteπaπa Porter's violet
Viola x primulifolia violet
Viola x ravida violet
Viola x redacta violet
Viola x ryoniae Ryon's violet
Viola x slavinii Slavin's violet
Viola wittrockiana, ladies' delight, etc
Viola x wujekn Viola x wujekn
Viola yedoensis Viola yedoensis
The most important species of the Viola genus include Viola tricolor, Viola arvensis and Viola odorata.
Under ,,a part of a plant or herb that has grown above the earth" the leaf and/or stem and/or flowers (inflorescence) of the plant is/are meant.
The extract is prepared in a manner known perse. For this purpose, the part of the herb that has grown above the earth,
optionally after drying and size-reducing, is extracted. The extraction is carried out with water or an organic solvent such as an alcohol e.g. ethanol, or an aqueous solution of an organic solvent e.g. aqueous ethanol generally at 0-100 0C, preferably at 20-100 0C. During the extraction, in most cases, mixing is applied, however, ultrasonication can be used, too. The extract is separated from the parts of the plant by known methods using e.g. sedimentation, pressing of the parts of the plant, filtration, centrifugation or the combination of the procedures listed. The extract obtained can be used as it is or it can be converted to a liquid composition or pharmaceutical composition such as an aqueous solution or syrup. However, it is preferred to remove the solvent content of the extract for example by evaporation, spray drying or freeze drying, and the solid residue is used as an active agent for the preparation of a composition or a pharmaceutical composition. (In the description and claims, the expression ,,active agent" is used in this sense and it refers to the solid residue that is dissolved in the extract and can be obtained from the extract of the medicinal herb.) Both the extract and the solid residue obtained from the extract can be characterized by the determination of the flavonoid and polyphenol contents. For example, the flavonoid content of the solid residue amounts to 2.8-3.4 g/100 g, and the total polyphenol content is 9.7-11.0 g/100 g.
Under a pharmaceutical composition" a known formulation or dosage form is meant which is conventionally used for the
prevention or treatment of diseases and which is suitable for peroral, parenteral, rectal or transdermal administration or for local treatment. Thus, the pharmaceutical composition of the invention is solid or liquid and contains, in addition to the active substance obtained from the medicinal herb by extraction, one or more pharmaceutical carrier(s). The pharmaceutical composition of the invention contains, in general, 0.1-100 % by mass, preferably 1-50 % by mass, suitably 5-30 % by mass of the active ingredient. It is to be noted that a 100 % content of active ingredient is possible only in certain cases e.g. in capsules where dilution is not absolutely necessary. In most dosage forms, diluents and/or other auxiliary agents are needed for the preparation of the pharmaceutical composition.
The solid pharmaceutical compositions suitable for peroral administration may be powders, capsules, tablets, film-coated tablets, microcapsules etc., and can comprise binding agents such as gelatine, sorbitol, poly(vinylpyrrolidone) etc.; filling agents such as lactose, glucose, starch, calcium phosphate etc.; auxiliary substances for tabletting such as magnesium stearate, talc, poly(ethylene glycol), silica etc.; wetting agents such as sodium laurylsulfate etc. as the carrier.
The liquid pharmaceutical compositions suitable for peroral administration may be solutions, suspensions or emulsions and can comprise e.g. suspending agents such as gelatine, carboxymethylcellulose etc.; emulsifiers such as sorbitane monooleate etc.; solvents such as water, oils, glycerol, propylene glycol, ethanol etc.; preservatives such as methyl or
propyl p-hydroxybenzoate etc. as the carrier.
Pharmaceutical compositions suitable for parenteral application contain, in general, a sterile solution of the active agent.
Pharmaceutical compositions suitable for local treatment include solutions, creams, liniments etc.
The dosage forms listed above as well as other dosage forms are known perse, see e.g. the manual Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, USA (1990)
The pharmaceutical composition contains dosage unit, in general. The daily dose can be administered in one or more portions. The actual dosage depends on many factors and is determined by the doctor. In general, a typical dose for adult patients of 70 kg body weight amounts to 0.1 to 10 g, preferably 1 to 5 g of active agent, daily.
In general, the pharmaceutical composition is prepared by admixing the active ingredient to one or more carrier(s) and transforming the mixture obtained into a pharmaceutical composition in a manner known perse. The methods that can be used are known from the literature e.g. the manual Remington's Pharmaceutical Sciences cited above. Of course, as a further possibility, the solid residue obtained from the extract can be directly filled into capsules or the extract itself can be converted to a liquid pharmaceutical composition by the addition of further carriers, if needed.
In cases when the extract or active ingredient of the
invention is applied to achieve mitochondrial genesis for e.g. roboration, muscle-building etc. purpose, the composition administered is not necessarily a pharmaceutical composition, however, the contents and preparation thereof corresponds to those of the pharmaceutical compositions described herein. Consequently, the expression ..composition" used in the description and claims without the marking ..pharmaceutical" refers to a dosage form that is applied to induce favourable biological effects related to mitochondrial genesis, however, such treatment is not definitely medication.
The effect of the medicinal herbs belonging to the order of Violales was studied by the following biological tests.
Cell cultures and cultural characteristics employed in the in vitro tests
Primary pig endothelial cell culture
The thoracic aorta of a pig was excised, aseptically, and placed into a PBS solution containing 50 μg/ml of streptomycin for transport (PBS is a physiological saline that contains phosphate buffer). The connective tissue was removed from the aorta which latter was cut to pieces of several cm length, and the rings obtained were opened. A sterile, close-meshed plastic net impregnated with trypsin (0.25 % of trypsin in PBS) was placed onto the surface covered by endothelium and the tissues were kept at 37 0C for 1 or 2 minute(s). The endothelium layer loosened under the action of trypsin was removed by washing, the cells were collected by centrifugation, then removed to culturing dishes coated with collagen and
grown in a 1 :1 mixture of DMEM (Dulbecco's modified Eagle's medium) culture medium (GibcoBRL, Eggenstein, Germany) supplemented with 10 % of FCS (fetal calf serum) and F-12. A homogenous culture was obtained in which more than 95 % of the cells showed endothelial morphology. The cells from the first ten passage were used in the tests.
Primary rat glia culture
The cortex of an 8 day's old Wistar rat was removed aseptically, cut into pieces, and the cells were set free by diggestion with trypsin (0.08 % of trypsin in PBS). The larger pieces of tissue were removed, the fraction containing individual cells and lumps consisting of some cells was washed twice with RPMI (Roswell Park Memorial Institute) culture medium containing 10 % of FCS. At last, the cells suspended in RPMI culture medium containing 10 % of FCS were placed into grow dishes (Greiner) without special surface treatment and grown at 37 0C under an atmosphere containing 5 % of carbon dioxide. A mixed cell culture was obtained containing mainly glia (astrocyte, oligodendrocyte and microglia) cells. Cells obtained in the first passage were used in the tests.
HaCaT cell culture
Human immortalized HaCaT skin cells were grown in a DMEM culture medium containing 10 % of FCS in dishes (Greiner) without special surface treatment at 37 0C under an atmosphere containing 5 % of carbon dioxide. The culture medium was supplemented with 25 mM or 50 mM of D-glucose and the cells were grown for at least 1 week in this culture
medium.
Quantitative determination and morphological study of mitochondria
Staining with the fluorescent stain MitoTracker
The cells were incubated with 100 nM of the fluorescent stain MitoTracker at 37 0C for 30 minutes. The stain cumulating in the active mitochondria exhibits a fluorescent emission at 516 nm following an excitation at 490 nm. The fluorescence of the mitochondria was determined partly in a microscope, partly using a FACS (fluorescence activated cell sorter) apparatus. For the determination with the microscope, a fluorescence microscope Zeiss-Axioskop was employed. Exposures were prepared with a Nicon Coolpix 995 digital camera using identical exposure time, diaphragm aperture and digital picture size. The exposures were evaluated by densitometry. The intensity of the cell fluorescence is proportional to the amount of mitochondria. In addition, the observation under a microscope allows the study of the morphology of the mitochondrial network.
Determination of a mitochondrion specific protein by means of Western blot
The cells were rinsed and collected in ice-cold PBS (pH=7.4) containing 5 mM of ethylenediaminetetraacetic acid (EDTA), 5 mM of sodium fluoride and 100 μM of Na3VO4. Lysis of the cell pellet was carried out on ice under weak shaking for 10 minutes in a buffer solution containing 250 mM of sodium chloride, 50 mM of HEPES [4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid] (pH=7,4), 1 mM of EDTA, 1 mM of EGTA [ethyleneglycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid], 1 ,5 mM of magnesium chloride, 0,1 % of Nonidet P-40 [nonylphenyl-poly(ethylene glycol)], 40 mM of β-glycerol phosphate, 1 mM of Na3VO4, 1 mM of phenylmethylsulfonyl fluoride, 10 mM of benzamidine, 20 mM of NaF, 10 mM of sodium pyrophosphate, 10 μM/ml of aprotinin, 10 μg/ml of leupeptin, and 10 μg/ml of antipain. The insoluble cell debris was removed by centrifugation (13000 g, 12 minutes, +4 0C). The clear supernatant was admixed to VT. volume of 2x Laemmli gel loading buffer, the samples were boiled for 3 minutes, then maintained at -20 0C before use. The protein concentration was determined by means of Bio-Rad D0 Protein Assay reagent (Bio-Rad Laboratories, Hercules, California, USA). Samples containing identical amount of protein were separated by polyacrylamide gel electrophoresis in the presence of 10 % of sodium dodecylsulfate (10 % SDS-PAGE) and blotted on PVDF [poly(vinylidene difluoride)] membrane using a Trans-Blot SD Blotting Kit (Bio-Rad Laboratories). The imune detection was carried out using anti-COX-IV antibody (A21348, Molecular Probes). Anti-mouse IgG HRP (horse radish peroxidase) conjugated antibody (Cell Signalling Technologies) was used as secondary antibody. For the detection, ECL (enhanced chemiluminescence) Plus System (Amersham) was employed.
Quantitative determination of stress proteins and cNOS on Western blot
The method is identical with the one described above. The following antibodies were used: anti-HSP72 (Citomarker Research & Development, Hungary), anti-HSP90 alpha (Affinity BioReagents, Golden, USA), anti-eNOS (Transduction Laboratories, USA), anti-HSP25 (Affinity BioReagents, Golden, USA).
The evaluation of the microscope exposures and Western blots was carried out densitometrically by means of a UTHSCA Image Tool Version 3.0 computer program. In case of the microscope exposures, three confluent cell layers selected randomly were examined. From the optical density values obtained, the mean value was determined. Statistical comparison and calculation were carried out by the one-way analysis of the difference using the Posthoc Newman-Keuls test (Pharmacological Calculation System). The statistical significance was p< 0.05.
Quantitative determination of nitric oxide in human lymphocyte in vitro
Human blood was drawn before use and heparin was added to inhibit clotting, then the blood was divided into two portions. One portion was treated at 37 0C for 3 hours with an aqueous solution containing 8 μg/ml of an active substance prepared from Viola tricolor by process A of Example 1. Then the nucleated cells were separated by centrifugation at Ficoll gradient, then DAF-FM [4-amino-5-methylamino-2',7'-difluoro- fluorescein diacetate, Molecular Probes] as fluorescent NO- indicator was added to the cells at a concentration of 2x10"6 M.
Following the reaction with nitric oxide, the fluorescence of DAF-FM (excitation peak at 490 nm, emission peak at 515 nm) becomes 160-times higher, therefore it is suitable for the measurement of the amount of intracellular NO. After incubation for 30 minutes, the DAF specific fluorescence of the cells in the lymphocyte cell fraction was determined by means of a Becton Dickinson FACS Calibur apparatus.
In vivo tests in animals
Study of the brown adipose tissue in mice
NMRI mice having a body mass of 23-25 g were treated, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 for 4 days. On day 5, the animals were anaesthetized by an injection of pentobarbital [5-ethyl-5-(1-methylbutyl)-2,4,6- (1 H,3H,5H)-pyrimidintrione], and samples were taken from the brown adipose tissue of the animals. Then, the level of proteins in the tissue was determined.
Test of glucose tolerance
Groups of male CFLP mice having a body mass of 25 g were treated, once daily, with a dose of 30 or 100 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 for 5 days, wherein each group consisted of 5 mice. On the fifth day, 1 hour after the treatment, the animals were anaesthetized by an injection of pentobarbital, blood was drawn from the corner of the eye and the glucose level was determined from the blood using an AccuCheck glucose meter. Then, 2 g of glucose/kg body weight were administered,
intraperitoneally, and blood glucose levels were determined in the animals 30, 60 and 90 minutes after the glucose administration. The mice of the control group were treated with an identical amount of the carrier (i.e. distilled water).
The results obtained by the treatment with the active substance prepared from Viola tricolor by process A of Example 1 are given in Table 1 at a later part of the description. The active substances prepared from Viola tricolor by processes B and C have shown rather similar activity, therefore these results are not shown in Table 1. Study of the intestinal motility in rats The test was carried out on rat ileum preparations according to Anjaneyulu [Anjaneyulu, M. and Pamarao, P.: Studies on gastrointestinal tract functional changes in diabetic animals, Methods Find. Exp. Clin. Pharmacol., 24, 71-75 (2002)]. In male Sprague-Dowley rats (Charles River Hungary) of 230-260 g body mass, diabetes was induced by the intravenous administration of 60 mg/kg of streptozocin. The blood sugar level of the animals was determined from the fourth week following the induction of diabetes, weekly, and the animals having stable high blood sugar level (>20 mM/litre) were drawn into the test after the tenth week. The 7 animals of the test group were treated orally, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 in aqueous solution for 5 days, while the 7 animals of the control group were treated with an identical volume of physiological saline. On the day after the
last treatment, the animals were anaesthetized by the administration of pentobarbital, the ileum was removed, cleaned, suspended in a Krebs-Henseleit's solution at 37 0C using 1 g of initial load, contracted with acetylcholine, then the relaxation ability of the ileum was evaluated based on the relaxation response to encreasing doses of isoproterenol [4-[1 - hydroxy-2-[(1-methylethyl)amino]ethyl]-1 ,2-benzenediol]. The measurements were carried out in an lsosys System apparatus (Experimetria, Budapest, Hungary).
Test of aorta relaxation in rat
The test was carried out on rat aorta preparations according to Kobayashi [Kobayashi, T. and Kamata, K.: Effect of insulin treatment on smooth muscle contractility and endothelium- dependent relaxation in rat aorta from established STZ- induced diabetes, Br. J. Pharmacol., ^27, 835-842 (1999)]. In male Sprague-Dowley rats (Charles River Hungary) of 270-290 g body mass, diabetes was induced by the intravenous administration of 60 mg/kg of streptozocin. The tests were started after 9-14 weeks following the induction of diabetes using animals having a stable high blood sugar level of above 20 mM/litre. The 7 animals of the test group were treated orally, once daily, with a dose of 30 mg/kg of the active substance prepared from Viola tricolor by process A of Example 1 in aqueous solution for 5 days, while the 7 animals of the control group were treated with an identical volume of physiological saline. On the day after the last treatment, the animals were anaesthetized by the administration of
pentobarbital, the thoracic aorta was removed and placed into ice cold Krebs' solution containing 118,0 mM of sodium chloride, 4,7 mM of potassium chloride, 2,52 mM of calcium chloride, 1 ,64 mM of magnesium sulfate, 24,88 mM of sodium hydrogen carbonate, 1 ,18 mM of potassium dihydrogen phosphate and 11 ,0 mM of D-glucose. A gas mixture consisting of 95 % of oxygen and 5 % of carbon dioxide was led through the solution, constantly. The descending aorta was cut to obtain rings of 5 mm width, the rings were suspended in a Krebs' solution at 370C using 2 g of initial load under constant introduction of the oxygen gas, contracted with phenylephrine [(R)-3-hydroxy-α-[(methylamino)methyl]- benzenemethanol], then the relaxation ability of the rings was determined based on the relaxation response to increasing doses of acetylcholin. The measurements were carried out in an lsosys System apparatus (Experimetria, Budapest, Hungary).
The following results were obtained in the tests: Increase of nitric oxide level in human lymphocyte, in vitro In the freshly isolated human blood lymphocytes, the intracellular nitric oxide level could be well determined using DAF fluorescent stain. The average DAF fluorescence that is in direct proportion to the amount of intracellular NO had a value of 448+105 relative units in the untreated samples (i.e. control), while in case of samples treated with an aqueous solution containing 8 μg/ml of an active substance prepared from Viola tricolor by process A of Example 1 , the average DAF
fluorescence had a value of 857+124 relative units. Thus, treatment with the active substance extracted from the medicinal herb Viola tricolor raised the intracellular NO concentration by 91 %.
Increase of the mitochondrial number An increase of the mitochondrial number due to the treatment with an aqueous solution containing 8 μg/ml of an active substance prepared from Viola tricolor by process A of Example 1 for 4 days was observed in primary pig endothelial cell culture. After staining with the fluorescent stain MitoTracker, the results were determined using either a fluorescence activated cell sorter (FACS) apparatus or a fluorescence microscope. In the evaluation of the results obtained, the optical density of the contrail cell culture was taken as unit and the optical densities of the treated cell cultures were compared with that of the control cell culture. Evaluation with the FACS apparatus indicated an increase of the mitochondrial number by 30 %, while the evaluation with the fluorescence microscope indicated an increase of the mitochondrial number by 60 % relative to the control value. The exposures prepared by using microscope and digital camera following the treatment with the active substance extracted from the medicinal herb Viola tricolor exhibited a strengthening of the mitochondrial network which is a sign of the vigorous active mitochondrial system.
In a primary rat glia cell culture, the treatment carried out with a dose of 16 ug/ml of the active substance prepared from
Viola tricolor in aqueous solution for 4 days resulted in a 20 % increase of the fluorescence characterizing the amount of mitochondria compared with the control. The strengthening of the mitochondrial network could be observed after the treatment in this case, too.
In addition to the direct determination of the mitochondrial number, an increase of the level of COX-IV protein could be also noticed on Western blot. It is to be noted that the COX-IV protein is specific of mitochondrion and plays a key role in oxidative phosphorylation, thus, the increase of the level thereof indicates the increase of the amount of mitochondria. It was found that the COX-IV protein level increased by 60 % compared with the control in the primary pig endothelial cell culture owing to the treatment for 4 days with a dose of 8 μg/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution. In case of the primary rat glia cell culture, the COX-IV protein level increased by 430 % compared with the control due to the treatment for 4 days with a dose of 16 μg/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution. Increase of the expression of cNOS and HSP Nitric oxide synthetized especially by the endothelial nitric oxide synthase (eNOS) enzyme is rather important in the regulation of mitochondrial function and biogenesis. Nitric oxide enhances the expression of the transcription factor PGC- 1α, the main regulator of mitochondrial biogenesis. Based on the Western blot examination, the amount of cytosolic eNOS
was higher by about 60 % in pig endothelial cells due to the treatment for 4 days with a dose of 8 μg/ml of the active substance prepared from the medicinal herb Viola tricolor in aqueous solution. Cytosolic eNOS is considered to be active. The heat shock proteins (chaperons) HSP72 and HSP90 are extremely important in the formation and stabilization of the functionally active eNOS complex. Also according to the tests carried out on Western blot, the amount of HSP90α increased by 10 %, while the level of HSP72 increased by 130 % compared with the untreated control due to the treatment of the invention. It is to be noted that, in addition to the stabilization of the eNOS enzyme system, the HSP72 has a key role also in the import of mitochondrial proteins. This coordinated import of protein is essential for the normal mitochondrial function and biogenesis.
In general, a culture medium having a higher glucose content (25 mM) than the normal blood sugar level is used for growing human immortalized HaCaT keratinocyte cells. In the culture medium, the cells adapted themseves to the high glucose concentration. Therefore, in order to simulate the hyperglycaemic environment, the concentration of glucose was raised by further 25 mM and the cells were grown in this culture medium. Based on staining with MitoTracker, the mitochondrion content of the cells grown in the culture medium containing 25 mM of glucose was higher by 30 % than that of the cells grown under hyperglycaemic circumstances in a culture medium containing 50 mM of glucose. This observation
corresponds to the known fact that a hyperglycaemic environment deteriorates mitochondria. The cell culture pretreated with 50 mM of glucose was treated for 4 days with a dose of 4 μg/ml of the active substance prepared from the medicinal herb Viola tricolor. The treatment raised the amount of mitochondria by 20 % i.e. the treatment could partly combat the hyperglycaemic effect.
In the HaCaT keratinocyte cells grown in a hyperglycaemic environment, the proteins examined by us and having a key role in the mitochondrial genesis were expressed only in the smallest amount. However, in the cells treated for 4 days with a dose of 4 μg/ml of the active substance prepared from the medicinal herb Viola tricolor, the amount of PGC-1α increased by a factor of 8, that of HSP90α and HSP72 increased by a factor of 6, that of HSP60 increased by a factor of 3 and that of COX-IV protein increased by a factor of 3.
The above test results prove unambiguously that the treatment of the invention enhances mitochondrial genesis and inhibits mitochondrial damage, in vitro.
The brown adipose tissue of NMRI mice treated for 4 days with a dose of 30 mg/kg of the active substance prepared from the medicinal herb Viola tricolor contained the heat shock protein HSP90α in a higher amount by 120 % and the heat shock proteins HSP72 and HSP60 in a higher amount by 60 % compared with the control group without treatment. Due to the treatment, the level of heat shock protein HSP25 having an important role in the regulation of the redox processes of cells
was also higher by 60 %. This in vivo test result indicates that the active substance extracted from the medicinal herb Viola tricolor is absorbed and exerts its effect also in vivo.
The treatment of the invention improved also the glucose tolerance in mouse. The blood sugar levels expressed in nM and determined before the i.p. administration of 2 g/kg of D- glucose (0 minute), then after 30, 60 and 90 minutes following the administration are given in Table I for the control group and the test groups treated with an i.p. dose of 30 or 100 mg/kg of the active substance extracted from the medicinal herb Viola tricolor.
Table I
From Table I it can be seen that the intraperitoneal administration of glucose in a dose of 2 g/kg resulted in a significant increase of the blood sugar level in the control mice. In the control group, from the starting level of 12 mM (note that
the animals had not been starved before the test), the glucose concentration raised to as high as 22 mM 30 minutes after the treatment, and even 90 minutes after the treatment the glucose concentration was higher by 5 mM than the starting value. In case of animals treated with an i.p. dose of 30 mg/kg of the active substance extracted from the medicinal herb Viola tricolor, the increase of blood sugar level was slow, and even the highest blood sugar concentration did not exceed a value of 18 mM. The i.p. administration of 100 mg/kg of the active substance extracted from the medicinal herb Viola tricolor raised the blood glucose level by about 2 mM in 30 minutes, and after 60 minutes, the starting blood sugar level was restored. In summary, it can be stated that, in both dosage levels examined, the active substance extracted from the medicinal herb Viola tricolor reduced, significantly, the increase of blood glucose level induced by the glucose load, thus, improved the glucose tolerance of the animals.
Toxicity test
5 male NMRI white mice having a body mass of 23-25 g were treated, once, with a dose of 200 mg/kg of the active substance, intraperitoneally. The behaviour of the animals was evaluated for a week, neither any change of behaviour, nor weight loss was experienced. Thus, it can be stated that an i.p. dose of 200 mg/kg of the active substance extracted from the medicinal herb Viola tricolor does not result in an acute toxic effect in mice.
Restoration of reduced intestine relaxation
The intestine motility test described above which was carried out on the ileum isolated from artificially diabetic rats gave the results summarized in Table II.
Table Il
The data of Table Il show that the contraction developed with acetylcholin is considerably compensated by isoproterenol on the ileum of healthy animals in the control group. Treatment with streptozocin reduced the relaxation significantly, however, treatment with the active substance extracted from Viola tricolor restored the relaxation ability of the ileum. Correction of damaged relaxation of vessel The results shown in Table III were obtained in the test of aorta relaxation of artificially diabetic rats.
Table
The data of Table III indicate that in animals treated with streptozocin, the relaxation of vessel was reduced to a third of the value obtained in healthy animals. Treatments with the active substance extracted from Viola tricolor improved the relaxation of vessel significantly.
The above in vitro and in vivo tests prove that an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient enhances the mitochondrial genesis and compensates the reduced function of the constitutive nitric oxide synthase enzyme. The effect on mitochondrial genesis becomes pronounced when the usual mitochondrial content of the cells is reduced by a pathological
effect e.g. hyper-glycaemia. In the background of the increase of mitochondrial genesis, an enhanced expression and function of chaperon and cNOS proteins were observed. Nitric oxide that depends on cNOS stimulates mitochondrial biogenesis and increases the expression of transcription factors that regulate biogenesis. The chaperons (HSP70, HSP90, HSP60, HSP27) partly contribute to the formation and stabilization of the functionally active cNOS complex, partly have an important role in the transport of mitochondrial proteins as well as in the compensation of any oxidative load (e.g. hyperglycaemia).
Therefore, it is expected that an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient provides for a curing effect in case of disorders owing to a damage of the mitochondrion or a reduced function of the cNOS enzyme; advantages can be awaited in states or diseases when an increase of mitochondrial genesis is useful; furthermore, diseases connected with a damage of the mitochondrion or the reduced function of the cNOS enyzme can be prevented by applying said extract or active ingredient.
An extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient can be effective especially in the following states:
I. Through exerting an influence on the mitochondrial function and promoting the mitochondrial biogenesis a) States and diseases requiring fast mitochondrial regeneration:
- long-lasting immobilization, states following a disease accompanied by weight loss,
- regeneration phase of anorexia. b) States requiring increased mitochondrial demand:
- muscle (especially striated muscle) developing training,
- sudden loading of the muscles (especially striated muscles) and the subsequent period,
- muscular strain
- adaptation to high-altitude. c) States accompanied by increased mitochondrial loss or damage:
- oxidative damage,
- myocardial damages caused by hypoxia-reoxigenation, c-i ) diseases connected with the mitochondrial DNA:
- myoclonus epilepsy and ragged red fibers syndrome,
- leber hereditery optic neuropathy,
- MLAS,
- Leight's disease,
- Kern-Sayre's syndrome,
- chronic progressive external ophtalmoplegia,
- Alper's syndrome,
C2) neurodegenerative diseases which are not connected with the mitochondrial DNA:
- ALS (amyotrophic lateral sclerosis),
- Huntington's disease,
- Alzheimer's disease,
- Parkinson's disease. d) Mitochondrial damage caused by exogenic agents:
- states that follow the damage of skin surface owing to ultraviolet light (such as a sunburn or a precancerous state). e) Myopathies, especially certain forms of cardiomyopathy.
II. Treatment or prevention of metabolic diseases caused by insufficient mitochondrial function:
- diabetes
- insulin resistance,
- metabolic syndrome
- obesity.
III. Slowing of aging that has been accelerated due to mitochondrial damages.
IV. Other application possibilities due to improvement of cNOS function: a) Motility disorders of the gastrointestinal system:
- achalasia,
- infantile hypertrophic pylorus stenosis,
- Hirschprung's disease,
- diabetic gastropathy,
- reflux oesophagitis,
- gastrointestinal function disorder in case of diabetes,
- gastroparesis,
- functional dyspepsia,
- intestinal pseudoobstruction and colitis,
- common motility disorders of the gastrointestinal system (e.g. obstipation),
- dysfunction of sphincters (e.g. pyloric sphincter, sphincters of the anus). b) Gall bladder dysfunctions:
- biliary dyskinesia,
- formation of gallstone,
- dyslipidemia,
- types Il and III biliary and pancreatic sorts of sphincter of Oddi dysfunction (SOD),
- post-cholecystectomy syndrome, c) Functional disorders of urinary bladder:
- neurogen urinary retention,
- urinary disorder in diabetes. d) Erectile dysfunctions:
- neurogen erectile dysfunction. e) Impaired fertility. f) Muscle degeneration:
- Duchene muscular dystrophy. g) Traumatic peripheral nerve lesion, h) Nephrosis, traumatic renal demage. i) Disorders of the blood circulation:
- arteriosclerosis,
- vasoconstriction. j) Damages caused by smoking especially vasoconstriction,
thrombosis, arteriosclerosis, chronic bronchitis, pulmonary emphysema.
Thus, the composition or pharmaceutical composition of the invention containing an extract of a part of a medicinal herb belonging to the order of Violates, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is suitable for:
- exerting an influence on the mitochondrial function and promoting the mitochondrial biogenesis;
- the treatment or prevention of metabolic diseases caused by insufficient mitochondrial function;
- slowing of aging that has been accelerated due to mitochondrial damages;
- various application possibilities due to improvement of cNOS function, as listed above under items I, II, III and IV.
A preferred embodiment of the invention refers to the use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a composition suitable for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal.
A preferred embodiment of the composition of the invention containing the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown
above the earth, as the active ingredient and one or more carrier(s) is suitable for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal.
A preferred composition of the invention is a roborant composition that improves the physical condition of the body after illness or anorexia or in case of muscle development trainings.
Furthermore, a preferred embodiment of the invention refers to the use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a pharmaceutical composition suitable for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases comprising ALS, Parkinson's disease, Alzheimer's disease and Atkinson's disease, and/or myopathies comprising cardiomyopathy, and/or metabolic diseases comprising diabetes, insulin resistance, metabolic syndrome and obesity, and/or motility disorders of the gastrointestinal system comprising achalasia, infantile hypertrophic pylorus stenosis, Hirschprung's disease, diabetic gastropathy, reflux oesophagitis, gastrointestinal function disorder in case of diabetes, gastroparesis, functional dyspepsia, intestinal pseudoobstruction, colitis, common motility disorders of the gastrointestinal system and dysfunction of sphincters, and/or gall bladder dysfunctions
comprising biliary dyskinesia, formation of gallstone, dyslipidemia and types Il and III biliary and pancreatic sorts of sphincter of Oddi dysfunction (SOD), post-cholecystectomy syndrome, and/or damage of the skin surface owing to ultraviolet light, and/or myocardial damages caused by hypoxia-reoxigenation and/or disorders of the blood circulation comprising arteriosclerosis and vasoconstriction.
A preferred embodiment of the pharmaceutical composition of the invention containing the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, as the active ingredient and one or more pharmaceutical carrier(s) is suitable for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases comprising ALS, Parkinson's disease, Alzheimer's disease and Atkinson's disease, and/or myopathies comprising cardiomyopathy, and/or metabolic diseases comprising diabetes, insulin resistance, metabolic syndrome and obesity, and/or motility disorders of the gastrointestinal system comprising achalasia, infantile hypertrophic pylorus stenosis, Hirschprung's disease, diabetic gastropathy, reflux oesophagitis, gastrointestinal function disorder in case of diabetes, gastroparesis, functional dyspepsia, intestinal pseudoobstruction, colitis, common motility disorders of the gastrointestinal system and dysfunction of sphincters, and/or
gall bladder dysfunctions comprising biliary dyskinesia, formation of gallstone, dyslipidemia and types II and III biliary and pancreatic sorts of sphincter of Oddi dysfunction (SOD), postcholecystectomy syndrome, and/or damage of the skin surface owing to ultraviolet light, and/or myocardial damages caused by hypoxia-reoxigenation and/or disorders of the blood circulation comprising arteriosclerosis and vasoconstriction.
A preferred pharmaceutical composition of the invention is suitable for the prevention or treatment of the motility disorders of the gastrointestinal system, thus, a preferred pharmaceutical composition of the invention is a prokinetic agent that induces movement in the gastrointestinal system.
An especially preferred pharmaceutical composition of the invention is suitable for the prevention or treatment of reflux oesophagitis.
The invention includes a method for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme, especially neurodegenerative diseases, myopathies, metabolic diseases, motility disorders of the gastrointestinal system, gall bladder dysfunctions, disorders of the blood circulation or damage of the skin surface owing to ultraviolet light in which the patient being in need thereof is treated with a therapeutically effective amount of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the
earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient.
The invention is further elucidated by means of the following Examples.
Example 1 Preparation of an extract
Process A
10O g of the dry, finely powdered parts of Viola tricolor grown over the earth (i.e. leaf, stem, flowers) are extracted with water in a mass ratio of 5:200 at 60 0C under intensive stirring over a water bath. The aqueous extract obtained is filtered, the plant matter is pressed, then the extract is sedimented for 4-8 hours, and filtered again. The dry matter content of the aqueous extract obtained amounts to 5.5-5.9 mg/ml. The water is removed by lyophilization while maintaining the temperature of the tray under -50 0C. The dry residue obtained is stored in darkness at room temperature and protected from moisture. The dry matter (i.e. the active substance) has a flavonoid content of 3.0-3.4 g/100 g, total polyphenol content of 9.7-10.0 g/100 g , and total content of polyphenol in the skin powder of 2.0-2.5 g/100 g.
Process B
100 g of the dry, powdered parts of Viola tricolor grown over the earth (i.e. leaf, stem, flowers) are extracted with water in a mass ratio of 5:150 by boiling at 100 0C. The aqueous extract obtained is worked up as described under process A. The aqueous extract has a dry matter content of 5.7-6.2 mg/ml. The
lyophilized product (i.e. active substance) prepared as given under process A has a flavonoid content of 2.8-3.1 g/100 g, total polyphenol content of 10.1-11.0 g/100 g , and total content of polyphenol in the skin powder of 1.9-2.2 g/100 g.
Process C
100 g of the dry, powdered parts of Viola tricolor grown over the earth (i.e. leaf, stem, flowers) are extracted with aqueous ethanol containing 75 % by volume of ethanol in a mass ratio of 5:200 in a cold ultrasonic bath. The extract is filtered and the ethanol is removed by evaporation under reduced pressure. The remaining aqueous phase is dried by lyophilization as described under process A.
Example 2 Preparation of capsules
0.5 g portions of the lyophilized active substance prepared according to Example 1 , process B are filled into hard gelatin capsules, the capsules are closed, placed into a glass container that is sealed airtightly..
Example 3 Preparation of syrup
To 1000 ml of the aqueous extract prepared according to Example 1 , process A (dry matter content: 5.8 mg/ml), 20 ml of glycerol, 100 ml of 70 % aqueous sorbitol solution, 0.1 g of aroma substance and 1 g of methyl paraben are added, the mixture is homogenized and filled into bottles of 50 ml.
Claims
1. Use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a composition suitable for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal.
2. A composition for enhancing the energy supply of the cells through mitochondrial genesis thereby strengthening the organism of a mammal comprising the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, as the active ingredient and one or more carrier(s).
3. A composition of Claim 2 which is a roborant composition.
4. Use of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, for the preparation of a pharmaceutical composition suitable for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases, myopathies, metabolic diseases, motility disorders of the gastrointestinal system, gall bladder dysfunctions, disorders of the blood circulation or damage of the skin surface owing to ultraviolet light.
5. A pharmaceutical composition for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxide synthase enzyme, especially neurodegenerative diseases, myopathies, metabolic diseases, motility disorders of the gastrointestinal system, gall bladder dysfunctions, disorders of the blood circulation or damage of the skin surface owing to ultraviolet light comprising the solid residue remaining after the removal of the solvent content of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, as the active ingredient and one or more pharmaceutical carrier(s).
6. A pharmaceutical composition of Claim 5 suitable for the prevention or treatment of motility disorders of the gastrointestinal system.
7. A method for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme, especially neurodegenerative diseases, myopathies, metabolic diseases, motility disorders of the gastrointestinal system, gall bladder dysfunctions, disorders of the blood circulation or damage of the skin surface owing to ultraviolet light in which the patient being in need thereof is treated with a therapeutically effective amount of an extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP0500813 | 2005-09-01 | ||
HU0500813A HUP0500813A2 (en) | 2005-09-01 | 2005-09-01 | Pharmaceutical composition containing violaceae extract |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007026185A2 true WO2007026185A2 (en) | 2007-03-08 |
WO2007026185A3 WO2007026185A3 (en) | 2007-04-26 |
Family
ID=89986242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2006/000071 WO2007026185A2 (en) | 2005-09-01 | 2006-08-30 | A pharmaceutical composition containing an extract of a medicinal herb belonging to the order of violales |
Country Status (2)
Country | Link |
---|---|
HU (1) | HUP0500813A2 (en) |
WO (1) | WO2007026185A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208504A (en) * | 2014-08-25 | 2014-12-17 | 闫立海 | Traditional Chinese medicine composition for treating gastrosis |
EP3062807A4 (en) * | 2013-10-28 | 2017-06-14 | Korea Institute of Oriental Medicine | Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity |
EP3868220A4 (en) * | 2018-10-17 | 2022-08-10 | Korea Institute of Oriental Medicine | Composition comprising flavonoid-based compound as active ingredient for preventing, alleviating, or treating sleep disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960016197B1 (en) * | 1993-04-09 | 1996-12-06 | 주식회사 엘지화학 | Cosmetic compositions containing natural uv break agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO103683B1 (en) * | 1989-02-27 | 1992-03-26 | Gheorghe Dutescu | Treatment medicine for eczema |
JP2000159622A (en) * | 1998-12-01 | 2000-06-13 | Naris Cosmetics Co Ltd | Cosmetic |
-
2005
- 2005-09-01 HU HU0500813A patent/HUP0500813A2/en unknown
-
2006
- 2006-08-30 WO PCT/HU2006/000071 patent/WO2007026185A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960016197B1 (en) * | 1993-04-09 | 1996-12-06 | 주식회사 엘지화학 | Cosmetic compositions containing natural uv break agents |
Non-Patent Citations (5)
Title |
---|
CHANG R S ET AL: "INHIBITION OF GROWTH OF HUMAN IMMUNODEFICIENCY VIRUS IN-VITRO BY CRUDE EXTRACTS OF CHINESE MEDICINAL HERBS" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 9, no. 3, 1988, pages 163-176, XP009076096 ISSN: 0166-3542 * |
DATABASE WPI Week 199325 Derwent Publications Ltd., London, GB; AN 1993-203635 XP002418568 & RO 103 683 A (BOICESCU M) 25 March 1992 (1992-03-25) * |
DATABASE WPI Week 200042 Derwent Publications Ltd., London, GB; AN 2000-477754 XP002418567 & JP 2000 159622 A (NARISU KESHOHIN KK) 13 June 2000 (2000-06-13) * |
PERWAIZ S ET AL: "ANTITUMORIGENIC EFFECT OF CRUDE EXTRACT OF VIOLA ODORATA ON DMBA-INDUCED TWO STAGE SKIN CARCINOGENESIS IN THE SWISS ALBINO MICE" ASIA PACIFIC JOURNAL OF PHARMACOLOGY, SINGAPORE UNIVERSITY PRESS, SG, vol. 13, no. 1, March 1998 (1998-03), pages 43-50, XP009076097 ISSN: 0217-9687 * |
RANA T S ET AL: "ETHNOBOTANICAL OBSERVATION AMONG JAUNSARIS OF JAUNSAR-BAWAR, DEHRA DUN (U.P.), INDIA" INTERNATIONAL JOURNAL OF PHARMACOGNOSY, SWETS & ZEITLINGER, LISSE, NL, vol. 35, no. 5, December 1997 (1997-12), pages 371-374, XP009034077 ISSN: 0925-1618 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3062807A4 (en) * | 2013-10-28 | 2017-06-14 | Korea Institute of Oriental Medicine | Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity |
CN104208504A (en) * | 2014-08-25 | 2014-12-17 | 闫立海 | Traditional Chinese medicine composition for treating gastrosis |
EP3868220A4 (en) * | 2018-10-17 | 2022-08-10 | Korea Institute of Oriental Medicine | Composition comprising flavonoid-based compound as active ingredient for preventing, alleviating, or treating sleep disorders |
US11903957B2 (en) | 2018-10-17 | 2024-02-20 | Korea Institute Of Oriental Medicine | Composition for preventing, ameliorating, or treating sleep disturbance comprising flavonoid compound as effective component |
Also Published As
Publication number | Publication date |
---|---|
WO2007026185A3 (en) | 2007-04-26 |
HUP0500813A2 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102478533B1 (en) | Compositions and methods for managing weight | |
US7276257B2 (en) | Schisandrin B preparation | |
KR100523562B1 (en) | Neuroprotective composition comprising an extract from opuntia ficus-indica and compounds isolated therefrom | |
CN109771431A (en) | The new application of honokiol derivative | |
JP2005508974A6 (en) | Pharmaceutical composition using prickly pear cactus extract or compound isolated therefrom for protection of nerve cells | |
WO2007083594A1 (en) | Laxative and food containing the same | |
WO2007026185A2 (en) | A pharmaceutical composition containing an extract of a medicinal herb belonging to the order of violales | |
WO2007026184A2 (en) | A pharmaceutical composition containing an extract of a solidago species | |
ITRM20000387A1 (en) | FOOD SUPPLEMENT USEFUL TO PREVENT HEPATIC AND BILIARY DYSFUNCTIONS INCLUDING AN ALCANOIL L-CARNITINE. | |
CN113521060B (en) | Application of NEEDOLIDE in resisting novel coronavirus | |
Wadood et al. | Effect of Ficus relegiosa on blood glucose and total lipid levels of normal and alloxan diabetic rabbits | |
US6221358B1 (en) | Method for lowering blood alcohol concentration by administering an extract of Rhus verniciflua | |
Amudhan et al. | Protective effect of areca catechu extract on ethanol induced gastric mucosal lesions in rats | |
KR100529991B1 (en) | An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug | |
KR19990066786A (en) | Liver function improver using Bergenin and its derivatives as active ingredients | |
KR100201585B1 (en) | Vasodilator composition | |
KR20060007152A (en) | Pharmaceutical composition for accelerating alcohol metabolism and inhibiting alcoholic liver injury comprising old platycodon extracts as an effective components | |
KR100447332B1 (en) | Novel Woowhangchungshimwon compositions and the preparation method thereof | |
Yadav et al. | IN-VITRO ANTI-DIABETIC ACTIVITY AND PHYTOCHEMICAL SCREENING OF ETHANOLICEXTRACT OF CALOTROPIS GIGANTEA (Linn). | |
US20210106636A1 (en) | Pharmaceutical composition comprising cannabinoid | |
KR100545382B1 (en) | The extracts of Pueraria flos which is effective on improvement of stress symptoms | |
Vijaykumar | Evaluation of Anti Asthmatic Activity of Urtica Dioica (Linn.) Leaves and Its Phytochemical Studies | |
KR20030083360A (en) | Active fraction having inhibitory effects on adipocytes (nih3t3-l1 cell) isolated from achyranthes japonica | |
KR20040100404A (en) | Active fraction having inhibitory effects on adipocytes (NIH3T3-L1 cell) isolated from medicinal plants | |
Aragão et al. | 07. Endocrine and Gastrointestinal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06779691 Country of ref document: EP Kind code of ref document: A2 |